CA2201785C - New carboxylic acid derivatives, their preparation and their use - Google Patents

New carboxylic acid derivatives, their preparation and their use Download PDF

Info

Publication number
CA2201785C
CA2201785C CA002201785A CA2201785A CA2201785C CA 2201785 C CA2201785 C CA 2201785C CA 002201785 A CA002201785 A CA 002201785A CA 2201785 A CA2201785 A CA 2201785A CA 2201785 C CA2201785 C CA 2201785C
Authority
CA
Canada
Prior art keywords
enantiomer
compound
alkyl
formulation
phenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CA002201785A
Other languages
French (fr)
Other versions
CA2201785A1 (en
Inventor
Hartmut Riechers
Dagmar Klinge
Wilhelm Amberg
Andreas Kling
Stefan Muller
Ernst Baumann
Joachim Rheinheimer
Uwe Josef Vogelbacher
Wolfgang Wernet
Liliane Unger
Manfred Raschack
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Royalty Pharma Collection Trust
Original Assignee
Abbott GmbH and Co KG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=6530833&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2201785(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Abbott GmbH and Co KG filed Critical Abbott GmbH and Co KG
Publication of CA2201785A1 publication Critical patent/CA2201785A1/en
Application granted granted Critical
Publication of CA2201785C publication Critical patent/CA2201785C/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/34—One oxygen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/60—Three or more oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/95—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in positions 2 and 4
    • C07D239/96—Two oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
    • C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
    • C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D251/14—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom
    • C07D251/16—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom to only one ring carbon atom
    • C07D251/20—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom to only one ring carbon atom with no nitrogen atoms directly attached to a ring carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
    • C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
    • C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D251/26—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hetero atoms directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
    • C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
    • C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D251/26—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hetero atoms directly attached to ring carbon atoms
    • C07D251/30—Only oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
    • C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
    • C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D251/26—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hetero atoms directly attached to ring carbon atoms
    • C07D251/40—Nitrogen atoms
    • C07D251/48—Two nitrogen atoms
    • C07D251/52—Two nitrogen atoms with an oxygen or sulfur atom attached to the third ring carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyridine Compounds (AREA)

Abstract

Carboxylic acid derivatives have the formula (I), in which R to R6, X, Y, and Z have the meanings given in the description. Also disclosed is their preparation. These new compounds are useful for controlling diseases.

Description

NEW CARBOXYLIC ACID DERIVATIVES. THEIR PREPARATION
AND THEIR USE
The present invention relates to novel carboxylic acid deriva-tives, their preparation and use.
Endothelia is a peptide which is composed of 21 amino acids and is synthesized and released by the vascular endothelium. Endothe-lia exists in three isoforms, ET-1, ET-2 and ET-3. In the follow-ing text, "endothelia" or "ET" signifies one or all isoforms of endothelia. Endothelia is a potent vasoconstrictor and has a potent effect on vessel tone. It is known that this vasoconstric-lion is caused by binding of endothelia to its receptor (Nature, 3~, (1988) 411-415; FEBS Letters, 231, (1988) 440-444 and Biochem. Biophys. Res. Commun., 154, (1988) 868-875).
Increased or abnormal release of endothelia causes persistent vasoconstruction in the peripheral, renal and cerebral blood ves-sels, which may lead to illnesses. It has been reported in the literature that elevated plasma levels of endothelia were found in patients with hypertension, acute myocardial infarct, pulmo-nary hypertension, Raynaud's syndrome, atherosclerosis and in the airways of asthmatics (Japan J. Hypertension, 12, (1989) 79, J. Vascular Med. Biology 2_, (1990) 207, J. Am. Med.~Association 264, (1990) 2868).
Accordingly, substances which specifically inhibit the binding of endothelia to the receptor ought also to antagonize the various abovementioned physiological effects of endothelia and therefore be valuable drugs.
we have found that certain carboxylic acid derivatives are good inhibitors of endothelia receptors.
'Iize invention as bzroadly disclosed hereinafther relates to carboxylic acid derivatives of the formula I' N
s I \
R-Z-C-CH-Y ~ \X
R 5 I N ~.
where R is formyl, tetrazole , nitrile~ .a COON group or a radical which can be hydrolyzed to COON, and the'other sub-stituents have the following meanings:
Ra hydrogen, hydroxyl, NHa, NH(C1-C4-alkyl), N(Cl-C4-alkyl)2, halogen, Cl-C4-..alkyl, Cl-Ca-haloalkyl, C1-C4-alkoxy, C1-C4-haloalkoxy or~Cl-C4-alkylthio;
X nitrogen or CR14 where R14 is hydrogen or C=_5-alkyl, or CR14 forms together with CR3 a 5- or 6-membered alkylene or alkenylene ring which can be substituted by one or .
two C1_4-alkyl groups and in which in each case a methylene group can be replaced by oxygen, sulfur, -NH or -NC1_4-alkyl;
IS R3 hydrogen, hydroxyl, NH2, NH(C~,-C4-Alkyl), N(Cl-C4-alkyl)2, halogen, C1-C4-alkyl, C1-,C4-haloalkyl, C1-C4-alkoxy, Cl-C4-haloalkoxy, -NH-O-C1_4-alkyl, Cl-C4-alkylthio or CR3 is ' ~ linked to CR14 as indicated above to give a . 5- or ' 6-membered '~
ring; ' ~ -R4 and R5:(which can be identical or different):
phenyl or naphthyl,~whi.ch can~be substituted by one or'more of the following radicals: halogen, vitro, cyano, hydroxyl, C1-C4-alkyl, C1-C4-haloalkyl, C1-C4-alkoxy; C1-C4-haloalkoxy, -phenoxy, C1-C4-alkylthio, amino, Ci-C4-alkylainino or Cl-C~-di-alkylamino; or - - .
phenyl or naphthyl, which are connected together in the ortho positions via a direct linkage,Ia methylene, ethylene or ethenylene group,.an oxygen or sulfur atom or an SOZ-, NH- or N-alkyl group, or C3-C~-cycloalkyl; .
R6 hydrogen, C1-CB-alkyl; C3-C6-alkeayl, C3-C6-alkynyl or C3-CB-cycloalkyl, where each of these radicals can be substituted one or more times bp: halogen, vitro, cyano, Cl-C4-alkoxy, C3-C6-alkenyloxy, C3-C6-alkynyloxy, C1-Ca-alkyl-thio, C1-C4-haloalkoxy, C1-C4-alkylcarbonyl,'C1-C4-alkoxy- -carbonyl, C3_$=alkylcarbonylalkyl, C1-C4-alkylamino, ..
di=Cl-C4-alkylamino, phenyl or phenyl or phenoxy which is substituted one or more times, eg. one to three times, by halogen, mitro, cyano, C1-=C4-alkyl, C1-C4-haloalkyl, Cl-C4-alkoxy, C1-C4-haloalkoxy or C1-C4-alkylthio;
phenyl or naphthyl, each of which c_an be substituted by one or more-of the following radicals: halogen, vitro, cyano, hydroxyl, amino, Cl-C4-alkyl, Cl-C4-haloalkyl, C1-C4-alkoxy, C1-C4-haloalkoxy, pheno.~y, C1-C4-alkylthio, Cl-C4-alkylamino, C1-C4-dialkylamino, dioxomethylene ['sic) or dioxoethylene [sic);
a five- or six-niembered heteroaromatic moiety containing one to three nitrogen atoms and/or one sulfur or oxygen atom, which can carry one to four halogen atoms and/or one or two of the following radicals: Cl-C4-alkyl, Cl-C4-haloalkyl, Ci-C4-alkoxy, Cl-C4-haloalkoxy, Cl-C4-alkylthio, phenyl, phenoxy or phenylcarbonyl, it being possible for the phenyl radicals in turn to carry one to five halogen atoms and/or one to three of the following radicals: C1-C4-alkyl, Cl-C4-haloalkyl, Cl-C4-alkoxy, C1-C4-haloalkoxy and/or Cl-C4-alkylthio;
with the proviso that R6 can be hydrogen only when Z is not a single bond;
Y sulfur or oxygen or a single bond;
Z sulfur or oxygen or a single bond.
The compounds, and the intermediates.for preparing them, such as IV and VI, may have one or more asymmetrical substituted carbon atoms. Such compounds may be in the form of the pure enantiomers or pure diastereomers or a mixture thereof. The use of an enant-iomerically pure compound as active substance is preferred.
The present invention as claimed is however directed to the compounds of the following formula and to compositions containing the same:
R RZ
N
Rs-Z- i -CH Y~~ \ X
R ~ ~N
R~

wherein:

3a R~ is OH and OR7;
R~ is a) an alkali metal cation, one equivalent of an alkaline earth metal cation, an ammonium cation or an organic ammonium ion;
b) C3_8-cycloalkyl optionally substituted by one to three C»-alkyl;
c) C~_8-alkyl optionally substituted by one to five halogen or one of C~_a-alkoxy, C»-alkylthio, and phenyl or phenoxy optionally substituted by one to five halogen, or one to three of nitro, cyano, C~~_alkyl, C»-haloalkyl, C~.~-alkoxy, C»-haloalkoxy and C~_4-alkylthio;
d) Cs_6-alkenyl or C3_s-alkynyl optionally substituted with one to five halogen; and e) phenyl optionally substituted with one to five halogen, or one to three of nitro, cyano, C»-alkyl, C1~-haloalkyl, C~~-alkoxy, C1~-haloalkoxy and C~~-alkylthio;
R2 and R3 are, independently, halogen, C~~-alkyl, C~~-haloalkyl, C~.~-alkoxy, C»-haloalkoxy and C»-alkylthio;
X is N or CRB;
R8 is H or, together with R3, forms a 5- or 6-membered alkylene or alkenylene ring, one of the methylene group of the ring being optionally replaced by oxygen;
R4 and R5 are identical or different and having the following meaning: phenyl or naphthyl optionally substituted by one or more of halogen, nitro, cyano, hydroxyl, 3b mercapto, amino, C~_4-alkyl, C»-haloalkyl, C~_4-alkoxy, C~_4-haloalkoxy, C~_4-alkylthio, C»-alkylamino, di-C~_4-alkylamino, C»-akylcarbonyl or C~.~-alkoxycarbonyl, or phenyl or naphthyl, which are connected together in the ortho positions via a direct linkage, a methylene, ethylene or ethenylene group, an oxygen or sulfur atom or an S02-, NH- or N-alkyl group, or C3-C~-cycloalkyl;
R6 is C~_a-alkyl, C3_s-alkenyl, C3_6-alkynyl, or C3_a-cycloalkyl optionally substituted by one or more of halogen, C~_4- alkoxy, C3_6-alkenyloxy, C3_6-alkynyloxy, C~~-alkylthio, C~_4-haloalkyl, C~~-alkylamino, di-C~_4-alkylamino, C~_4-alkylcarbonyl or C,_4-alkoxycarbonyl, or phenyl or phenyloxy optionally substituted by one or more of halogen, nitro, cyano, C~_4-alkyl, C~_4-haloalkyl, C~.~-alkoxy, C~~-haloalkoxy, C~~-alkylthio.
Y is sulfur, oxygen or a single bond; and Z is sulfur or oxygen;
with the proviso that Rs is not unsubstituted C»-alkyl when R4 is unsubstituted phenyl, Z is oxygen and simultaneously R5 is methyl or hydrogen.
The present invention also relates to a compound having the formula (I):
Rz R4 ~/
Rs-Z-C-CH Y~~ X
(I

wherein:

3c X is CH;
Y is oxygen;
Z is oxygen;
R is COZH;
R2 is methyl;
R3 is methyl;
R4 is phenyl;
R5 is phenyl, and R6 is methyl, and salts thereof.
The invention also relates to a pharmaceutical formulation comprising a compound having the formula:

R4 ~
N
Rs-Z-C-CH Y~~ ~~X
II

wherein:
X is CH;
Y is oxygen;
Z is oxygen;
R is COZH;
R2 is methyl;
R3 is methyl;
R4 is phenyl;
R5 is phenyl;
R6 is methyl; and 3d pharmaceutically acceptable salts thereof, dispersed in a pharmaceutical buffer, diluent or excipient.
The invention, also relates to a compound of the formula:

I N
Rs-Z-C-CH Y~~ \\X
N=-RS R

wherein:
X is CH;
Y is oxygen;
Z is oxygen;
R is C02H;
R2 is methoxy;
R3 is methoxy;
R4 is phenyl;
R5 is phenyl, and Rs is methyl, and salts thereof.
The invention, also relates to a pharmaceutical formulation comprising a compound having the formula:

R4 ~/
~N
Rs-Z-C-CH Y~~ X
~N=

3e wherein:
X is CH;
Y is oxygen;
Z is oxygen;
R is C02H;
R2 is methoxy;
R3 is methoxy;
R4 is phenyl;
R5 is phenyl, and R6 is methyl, and pharmaceutically acceptable salts thereof, dispersed in a pharmaceutical buffer, diluent or excipient.
The invention furthermore relates to the use of the abovemen-tioned carboxylic acid derivatives for producing drugs, in par-ticular for producing eadothelin receptor inhibitors., The invention furthermore relates to the preparation of the com-pounds.of .the formula IV in enantiomerically pure form. Enantio-selective epoxidation of an olefin with two phenyl substituents is known (J. Org. Chew. ~, 1994, 4378-4380). We have now found, surprisingly, that even ester groups in these systems permit epoxidation is high optical purity. ~ ' The preparation of the compounds according to the invention where Z is sulfur or oxygen starts from the epoxides IV, which are ob-tained is a conventional manner, eg.~as described in J. March, Advanced Organic Chemistry, 2nd ed., 1983, page 862 and page 750, from the ketones II or the olefins III:
R \
\C-0 R5~ _ II O
R 4~C~R
to \C
Rs . III
Carboxylic acid derivatives of the general formula VI can be pre-pared by reacting the epoxides of the general formula IV (eg.
with R = ROOR1~ with alcohols or thiols of the general for-mula V where R6 and Z have the meanings stated in claim 1.
R
IV + R6ZH R - Z - C CH OH VI
V ~5 R R
To do this, compounds of the general formula IV are'heated with compounds of the formula V, in the molar ratio of about 1:1 to 1:7, preferably 1 to 3 mole equivalents, to 50-200°C, preferably 80-150°C.
The reaction can also take place in the presence of a diluent.
All solvents which are inert toward the reagents used can be used for this purpose.
Examples of such solvents or diluents are water, aliphatic, ali-cyclic and aromatic hydrocarbons, which may in each'case be chlo-rinated, such as hexane, cyclohexane, petroleum ether, naphtha, benzene, toluene, xylene, methylene chloride, chloroform, carbon tetrachloride, ethyl chloride and trichloroethylene, ethers such as diisopropyl ether, dibutyl ether, methyl tert-butyl ether, propylene oxide, dioxane and tetrahydrofuran, ketones such as acetone, methyl ethyl ketone, methyl isopropyl ketone and methyl isobutyl ketone, nitriles such as acetonitrile and propionitrile, alcohols, such as methanol, ethanol, isopropanol, butanol and ethylene glycol, esters such as ethyl acetate and amyl acetate, amides such as dimethylformamide, dimethylacetamide and N-methyl-pyrrolidone,~sulfoxides and sulfones, such as dimethyl sulfoxide UuSU/ 4~i~s1 CA 02201785 1997-04-03 and sulfolane, bases such as pyridine, cyclic ureas such as 1,3-dimethylimidazolidin-2-one and 1,3-dimethyl-3,4,5,6-tetra-hydro-2(1H)-pyrimidinone.
The reaction is preferably carried out at a temperature in the range from 0°C to the boiling point of the solvent or mixture of solvents.
The presence of a catalyst may be advantageous. Suitable cata-lysts are strong organic and inorganic acids, and Lewis acids.
Examples thereof are, inter alia, sulfuric acid, hydrochloric acid, trifluoroacetic acid, p-toluenesulfonic acid, boron tri-fluoride etherate and titanium(IV) alcoholates.
Compounds of the formula VI where R4 and R5 are cycloalkyl can also be prepared by subjecting compounds of the formula VI where R4 and R5 are phenyl, naphthyl, or phenyl or naphthyl substituted as described above, to a nuclear hydrogenation.
Compounds of the formula VI can be obtained in enantiomerically pure form by starting from enantiomerically pure compounds of the formula IV and reacting them in the manner described with com-pounds of the formula V.
It is furthermore possible to obtain enantiomerically pure com-pounds of the formula VI by carrying out a classical racemate resolution on racemic or diastereomeric compounds of the formula VI using suitable enantiomerically pure bases such as brucine, strychnine, quinine, quinidine, chinchonidine [sic], chinchonine [sic], yohimbine, morphine, dehydroabietylamine, ephedrine (-), (+), deoxyephedrine (+), (-), threo-2-amino-1-(p-nitrophe-nyl)-1,3-propanediol (+), (-), threo-2-(N,N-dimethylamino)-1-(p-nitrophenyl)-1,3-propanediol (+), (-) threo-2-amino-1-phenyl-1,3-propanediol (+), (-), a-methylbenzylamine (+), (-).
a-(1-naphthyl)ethylamine (+), (-), a-(2-naphthyl)ethylamine (+), (-), aminomethylpinane, N,N-dimethyl-1-phenylethylamine, N-methyl-1-phenylethylamine, 4-nitrophenylethylamine, pseudoephedrine, norephedrine, norpseudoephedrine, amino acid derivatives, peptide derivatives.
The compounds according to the invention where Y is oxygen, and the remaining substituents have the meanings stated under the general formula I, can be prepared, for example, by reacting the carboxylic acid derivatives of the general formula VI where the substituents have the stated meanings with compounds of the gen-eral formula VII

W ~ilrl i.'.~,.r. CA 02201785 1997-04-03 ' ~ 6 N
IS
VI + R ~ ~ X I
N -R
VII
where R15 is halogen or R16-SOZ-, where R16 can be C1-C4-alkyl, C1-C4-haloalkyl or phenyl. The reaction preferably takes place in one of the abovementioned inert diluents with the addition of a suitable base, ie. of a base which deprotonates the intermediate VI, in a temperature range from room temperature to the boiling point of the solvent.
Compounds of the formula VII are known, some of them can be bought, or they can be prepared in a generally known manner.
It is possible to use as base an alkali metal or alkaline earth metal hydride such as sodium hydride, potassium hydride or cal-cium hydride, a carbonate such as an alkali metal carbonate, eg.
sodium or potassium carbonate, an alkali metal or alkaline earth metal hydroxide such as sodium or potassium hydroxide, an organo-metallic compound such as butyllithium, or an alkali metal amide such as lithium diisopropylamide.
The compounds according to the invention where Y is sulfur, and the remaining substituents have the meanings stated under the general formula I, can be prepared, for example, by reacting car-boxylic acid derivatives of the general formula VIII, which can be obtained in a known manner from compounds of the general for-mula VI and in which the substituents have the abovementioned meanings, with compounds of the general formula IX, where R2, R3 and X have the meanings stated under general formula I.

s I + H S X -~ I
R - Z - C- CH- OS02R Is R R

VIII IX
The reaction preferably takes place in one of the abovementioned inert diluents with the addition of a suitable base, ie. a base which deprotonates the intermediate IX, in a temperature range from room temperature to the boiling point of the solvent.
It is possible to use as base, besides those mentioned above, or-ganic bases such as triethylamine, pyridine, imidazole or diaza-bicycloundecane.
Carboxylic acid derivatives of the formula VIa (Z in formula VI =
direct linkage) can be prepared by reacting epoxides of the for-mula IV with cuprates of the formula XI:
Ra IV + R2 Cu ( CN ) Li2 --~ R - C- CH- OH
RS R
XI VIa The cuprates can be prepared as described in Tetrahedron Letters 23, (1982) 3755.
Compounds of the formula I can also be prepared by starting from the corresponding carboxylic acids, ie. compounds of the formula I where R is COON, and initially converting these in a conven-tional manner into an activated form, such as a halide, an anhy-dride or imidazolide, and then reacting the latter faith an appropriate hydroxy compound HOR1~. This reaction can be carried out in the usual solvents and often requires addition of a base, in which case those mentioned above are suitable. These two steps can also be simplified, for example, by allowing the carboxylic acid to act on the hydroxy compound in the presence of a dehy-drating agent such as a carbodiimide.
In addition, it is also possible for compounds of the formula I
to be prepared by starting from the salts of the corresponding carboxylic acids, ie. from compounds of the formula I where R is COR1 and R1 is OM, where M can be an alkali metal cation or the equivalent of ari alkaline earth metal cation. These salts can be reacted with many compounds of the formula R1-A where A is a con-ventional nucleofugic leaving group, for example halogen such as chlorine, bromine, iodine or aryl- or alkylsulfonyl which is un-substituted or substituted by halogen, alkyl or haloalkyl, such as toluenesulfonyl and methylsulfonyl, or another equivalent leaving group. Compounds of the formula R1-A with a reactive sub-stituent A are known or can be easily obtained with general ex-pert knowledge. This reaction can be carried out in conventional solvents and advantageously takes place with the addition of a base, in which case those mentioned above are suitable.
The radical R in formula I may vary widely. For example, R is a group 15 where R1 has the following meanings:
a) hydrogen;
b) succinylimidoxy;
c) a five-membered heteroaromatic moiety linked by a nitrogen atom, such as pyrrolyl, pyrazolyl, imidazolyl and triazolyl, which may carry one or two halogen atoms, in particular fluo-rine and chlorine and/or one or two of the following radi-cals:
C1-C9-alkyl such as methyl, ethyl, 1-propyl, 2-propyl, 2-methyl-2-propyl, 2-methyl-1-propyl, 1-butyl, 2-butyl;
C1-C4-haloalkyl, in particular C1-C2-haloalkyl such as fluoromethyl, difluoromethyl, trifluoromethyl, chloro-difluoromethyl, dichlorofluoromethyl, trichloromethyl, 1-fluoroethyl, 2-fluoroethyl, 2,2-difluoroethyl, 2,2,2-tri-fluoroethyl, 2-chloro-2,2-difluoroethyl, 2,2-dichloro-2-fluoroethyl, 2,2,2-trichloroethyl and pentafluoroethyl;
Cl-C4-haloalkoxy, in particular C1-C2-haloalkoxy such as difluoromethoxy, trifluoromethoxy, chlorodifluoromethoxy, 1-fluoroethoxy; 2-fluoroethoxy, 2,2-difluoroethoxy, 1,1,2,2-tetrafluoroethoxy, 2,2,2-trifluoroethoxy, 2-chloro-1,1,2-trifluoroethoxy and pentafluoroethoxy, in particular trifluoromethoxy;
C1-C4-alkoxy such as methoxy, ethoxy, propoxy, 1-methylethoxy, butoxy, 1-methylpropoxy, 2-methylpropoxy, 1,1-dimethylethoxy, in particular methoxy, ethoxy,~ 1-methylethoxy;

Uu:au/ 4:raui CA 02201785 1997-04-03 , C1-C4-alkylthio such as methylthio, ethylthio, propylthio, 1-methylethylthio, butylthio, 1-methylpropylthio, 2-methyl-propylthio, 1,1-dimethylethylthio, in particular methylthio and ethylthio;
d) R1 furthermore a radical -~O) m N

where m is 0 or 1 and R~ and R8, which can be identical or different, have the following meanings:
hydrogen C1-C8-alkyl, in particular C1-C4-alkyl as mentioned above;
C3-C6-alkenyl such as 2-propenyl, 2-butenyl, 3-butenyl, 1-methyl-2-propenyl, 2-methyl-2-propenyl, 2-pentenyl, 3-pentenyl, 4-pentenyl, 1-methyl-2-butenyl, 2-methyl-2-butenyl, 3-methyl-2-butenyl, 1-methyl-3-butenyl, 2-methyl-3-butenyl, 3-methyl-3-butenyl, 1,1-dimethyl-2-propenyl, 1,2-dimethyl-2-propenyl, 1-ethyl-2-propenyl, 2-hexenyl, 3-hexenyl, 4-hexenyl, 5-hexenyl, 1-methyl-2-pent-enyl, 2-methyl-2-pentenyl, 3-methyl-2-pentenyl, 4-methyl-2-pentenyl, 3-methyl-3-pentenyl, 4-methyl-3-pentenyl, 1-methyl-4-pentenyl, 2-methyl-4-pentenyl, 3-methyl-4-pent-enyl, 4-methyl-4-pentenyl, l,l-dimethyl-2-butenyl, 1,1-dime-thyl-3-butenyl, 1,2-dimethyl-2-butenyl, 1,2-dimethyl-3-but-enyl, 1,3-dimethyl-2-butenyl, 1,3-dimethyl-3-butenyl, 2,2-dimethyl-3-butenyl, 2,3-dimethyl-2-butenyl, 2,3-dimethyl-3-butenyl, 1-ethyl-2-butenyl, 1-ethyl-3-butenyl, 2-ethyl-2-butenyl, 2-ethyl-3-butenyl, 1,1,2-trimethyl-2-propenyl, 1-ethyl-1-methyl-2-propenyl and 1-ethyl-2-methyl-2-propenyl, in particular 2-propenyl, 2-butenyl, 3-methyl-2-butenyl and 3-methyl-2-pentenyl;
C3-C6-alkynyl such as 2-propynyl, 2-butynyl, 3-butynyl, 1-methyl-2-propynyl, 2-pentynyl, 3-pentynyl, 4-pentynyl, 1-methyl-3-butynyl, 2-methyl-3-butynyl, l-methyl-2-butynyl, 1,1-dimethyl-2-propynyl, 1-ethyl-2-propynyl, 2-hexynyl, 3-hexynyl, 4-hexynyl, 5-hexynyl, 1-methyl-2-pentynyl, 1-methyl-2-pentynyl, 1-methyl-3-pentynyl, 1-methyl-4-pentynyl, 2-methyl-3-pentynyl, 2-methyl-4-pentynyl, 3-methyl-4-pentynyl, UUSU/451t31 CA 02201785 1997-04-03 4-methyl-2-pentynyl, 1,1-dimethyl-2-butynyl, 1,1-dimethyl-3-butynyl, 1,2-dimethyl-3-butynyl, 2,2-dimethyl-3-butynyl, 1-ethyl-2-butynyl, 1-ethyl-3-butynyl, 2-ethyl-3-butynyl and 1-ethyl-1-methyl-2-propynyl, preferably 2-propynyl, 2-butynyl, 1-methyl-2-propynyl and 1-methyl-2-butynyl, in particular 2-propynyl C3-Ce-cycloalkyl such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl and cycloheptyl, cyclooctyl, where these alkyl, cycloalkyi, alkenyl and alkynyl groups can each carry one to five halogen atoms, in particular fluorine or chlorine and/or one or two of the following groups:
C1-C4-alkyl, C1-C4-alkoxy, C1-C4-alkylthio, C1-C4-haloalkoxy as mentioned above, C3-C6-alkenyloxy, C3-C6-alkenylthio, C3-G6-alkynyloxy, C3-C6-alkynylthio, where the alkenyl and alkynyl constituents present in these radicals preferably have the abovementioned meanings;
C1-C4-alkylcarbonyl such as, in particular, methylcarbonyl, ethylcarbonyl, propylcarbonyl, 1-methylethylcarbonyl, butyl-carbonyl, 1-methylpropylcarbonyl, 2-methylpropylcarbonyl, 1,1-dimethylethylcarbonyl;
C1-C4-alkoxycarbonyl such as methoxycarbonyl, ethoxycarbonyl, propyloxycarbonyl, 1-methylethoxycarbonyl, butyloxycarbonyl, 1-methylpropyloxycarbonyl, 2-methylpropyloxycarbonyl, 1,1-dimethylethoxycarbonyl;
C3-C6-alkenylcarbonyl, C3-C6-alkynylcarbonyl, C3-C6-alkenyloxy-carbonyl and C3-C6-alkynyloxycarbonyl, where the alkenyl and alkynyl radicals are preferably defined as detailed above;
phenyl, unsubstituted or substituted one or more times, eg.
one to three times, by halogen, nitro, cyano, C1-C4-alkyl, C1-C4-haloalkyl, C1-C4-alkoxy, C1-C4-haloalkoxy or C1-C4-alkyl-thio, such as 2-fluorophenyl, 3-chlorophenyl, 4-bromophenyl, 2-methylphenyl, 3-nitrophenyl, 4-cyanophenyl, 2-trifluoro-, methylphenyl, 3-methoxyphenyl, 4-trifluoroethoxyphenyl, 2-methylthiophenyl, 2,4-dichlorophenyl, 2-methoxy-3-methyl-phenyl, 2,4-dimethoxyphenyl, 2-nitro-5-cyanophenyl, 2,6-difluorophenyl;

vv;.~Vi ~.r~ui CA 02201785 1997-04-03 di-C1-C4-alkylamino such as, in particular, dimethylamino, dipropylamino, N-propyl-N-methylamino, N-propyl-N-ethylamino, diisopropylamino, N-isopropyl-N-methylamino, N-isopropyl-N-ethylamino, N-isopropyl-N-propylamino;
R~ and R8 furthermore phenyl which can be substituted by one or more, eg. one to three, of the following radicals:
halogen, nitro, cyano, C1-C4-alkyl, C1-C4-haloalkyl, C1-C4-alkoxy, C1-C4-haloalkoxy or C1-C4-alkylthio, as mentioned above in particular;
or R~ and Re together form a C4-C7-alkylene chain which is closed to form a ring, is unsubstituted or substituted, eg.
substituted by C1-C4-alkyl, and may contain a heteroatom selected from the group consisting of oxygen, sulfur or nitrogen, such as -(CHz)4-, -(CHz)5-, -(CHz)6-, -(CHz)~-, - ( CHz ) z-O- ( CHz ) z-, -CHz-S- ( CHz ) 3-. - ( CHz ) z-O- ( CHz ) a-.
-NH-(CHz)3-, -CHz-NH-(CHz)z-, -CHz-CH=CH-CHz-, -CH=CH-(CHz)3-;
e) R1 furthermore a group (O) is o-(CHZ) p -s R
where k is 0, 1 and 2, p is 1, 2, 3 and 4 and R9 is C1-C4-alkyl, C1-C4-haloalkyl, C3-C6-alkenyl, C3-C6-alkynyl or unsubstituted or substituted phenyl, as mentioned above in particular.
f) R1 furthermore a radical OR1~, where R1~ is:
hydrogen, the cation of an alkali metal such as lithium, so-dium, potassium or the cation of an alkaline earth metal such as calcium, magnesium and barium or an environmentally com-patible organic ammonium ion such as tertiary C1-C4-alkyl-ammonium or the ammonium ion;
C3-C8-cycloalkyl as mentioned above, which may carry one to three C1-C4-alkyl groups;
C1-Ce-alkyl such as, in particular, methyl, ethyl, propyl, 1-methylethyl, butyl, 1-methylpropyl, 2-methylpropyl, 1,1-dimethylethyl, pentyl, 1-methylbutyl, 2-methylbutyl, 3-methylbutyl, 1,2-dimethylpropyl, 1,1-dimethylpropyl, 2,2-dimethylpropyl, 1-ethylpropyl, hexyl, 1-methylpentyl, Uv:.~U/ ~~'u1 CA 02201785 1997-04-03 ' ' 12 2-methylpentyl, 3-methylpentyl, 4-methylpentyl, 1,2-dimethyl-butyl; 1,3-dimethylbutyl, 2,3-dimethylbutyl, 1,1-dimethyl-butyl, 2,2-dimethylbutyl, 3,3-dimethylbutyl, 1,1,2-trime-thylpropyl, 1,2,2-trimethylpropyl, 1-ethylbutyl, 2-ethyl-butyl, 1-ethyl-2-methylpropyl, which can carry one to five halogen atoms, in particular fluorine and chlorine and/or one of the following radicals:
C1-C4-alkoxy, C1-C4-alkylthio, cyano, C1-C4-alkylcarbonyl, C3-Ce-cycloalkyl, C1-C4-alkoxycarbonyl, phenyl, phenoxy or phenylcarbonyl, where the aromatic radicals in turn can carry in each case one to five halogen atoms and/or one to three of the following radicals: vitro, cyano, C1-C4-alkyl, C1-C4-halo-alkyl, C1-C4-alkoxy, C1-C4-haloalkoxy and/or C1-C4-alkylthio, as mentioned above in particular;
a C1-Ce-alkyl as mentioned above, which can carry one to five halogen atoms, in particular fluorine and/or chlorine, and carries one of the following radicals: a 5-membered heteroaromatic moiety containing one to three nitrogen atoms, or a 5-membered heteroaromatic moiety containing a nitrogen atom and an oxygen or sulfur atom, which can carry one to four halogen atoms and/or one or two of the following radicals:
vitro, cyano, C1-C4-alkyl, C1-C4-haloalkyl, C1-C4-alkoxy, phenyl, C1-C4-haloalkoxy and/or C1-C4-alkylthio. Particular mention may be made of: 1-pyrazolyl, 3-methyl-1-pyrazolyl, 4-methyl-1-pyrazolyl, 3,5-dimethyl-1-pyrazolyl, 3-phenyl-1-pyrazolyl, 4-phenyl-1-pyrazolyl, 4-chloro-1-pyrazolyl, 4-bromo-1-pyrazolyl, 1-imidazolyl, 1-benzimidazolyl, 1,2,4-triazol-1-yl, 3-methyl-1,2,4-tri-azol-1-yl, 5-methyl-1,2,4-triazol-1-yl, 1-benzotriazolyl, 3-isopropyl-5-isoxazolyl, 3-methyl-5-isoxazolyl, 2-oxazolyl, 2-thiazolyl, 2-imidazolyl, 3-ethyl-5-isoxazolyl, 3-phenyl-5-isoxazolyl, 3-tert-butyl-5-isoxazolyl;
a C2-C6-alkyl group which carries one of the following radicals in position 2: C1-C4-alkoxyimino, C3-C6-alkynyloxy-imino, C3-C6-haloalkenyloxyimino or benzyloxyimino;
a C3-C6-alkenyl or C3-C6-alkynyl group, it being possible for these groups in turn to carry one to five halogen atoms;
R1~ furthermore a phenyl radical which can carry one to five halogen atoms and/or one to three of the following radicals:
vitro, cyano, C1-C4-alkyl, C1-C4-haloalkyl, C1-C4-alkoxy, _ Uu~U/ 4~~~1 CA 02201785 1997-04-03 C1-C4-haloalkoxy and/or C1-C4-alkylthio, as mentioned above in particular;
a 5-membered heteroaromatic moiety which is linked via a nitrogen atom, contains one to three nitrogen atoms and can carry one or two halogen atoms and/or one or two of the following radicals: C1-C4-alkyl, C1-C4-haloalkyl, C1-C4-alkoxy, phenyl, C1-C4-haloalkoxy and/or C1-C4-alkylthio. Particular mention may be made of: 1-pyrazolyl, 3-methyl-1-pyrazolyl, 4-methyl-1-pyrazolyl, 3,5-dimethyl-1-pyrazolyl, 3-phenyl-1-pyrazolyl, 4-phenyl-1-pyrazolyl, 4-chloro-1-pyrazolyl, 4-bromo-1-pyrazolyl, 1-imidazolyl, 1-benzimidazolyl, 1,2,4-triazol-1-yl, 3-methyl-1,2,4-tri-azol-1-yl, 5-methyl-1,2,4-triazol-1-yl, 1-benzotriazolyl, 3,4-dichloro- 1-imidazolyl;
R1~ furthermore a group N CSR ~2 where Rll and R12, which can be identical or different, are:
C1-C8-alkyl, C3-C6-alkenyl, C3-C6-alkynyl, C3-Ce-cycloalkyl, it being possible for these radicals to carry a C1-C4-alkoxy, C1-C4-alkylthio andlor an unsubstituted or substituted phenyl radical, as mentioned above in particular;
phenyl which can be substituted by one or more, eg. one to three, of the following radicals: halogen, nitro, cyano, C1-C4-alkyl, C1-C4-haloalkyl, C1-C4-alkoxy, C1-C4-haloalkoxy or C1-C4-alkylthio, where these radicals are, in particular, those mentioned above;
or R11 and R1z together form a C3-C12-alkylene chain which can carry one to three C1-C4-alkyl groups and contain a heteroatom from the group consisting of oxygen, sulfur and nitrogen, as mentioned in particular for R7 and Re.
g) R1 furthermore a radical Uu~U/ 4~its1 CA 02201785 1997-04-03 ' 14 O

O
where R13 is:
C1-C4-alkyl, C3-C6-alkenyl, C3-C6-alkynyl, C3-Ce-cycloalkyl as mentioned above in particular, it being possible for these radicals to carry a C1-C4-alkoxy, C1-C4-alkylthio and/or a phenyl radical as mentioned above;
phenyl, unsubstituted or substituted, in particular as men-tioned above.
h) Rl a radical O

O
where Rla has the abovementioned meaning.
R can furthermore be:
tetrazole [sic] or nitrile [sic].
In respect of the biological effect, preferred carboxylic acid derivatives of the general formula I, both as pure enantiomers and pure diastereomers or as mixture thereof, are those where the substituents have the following meanings:
R2 hydrogen, hydroxyl, N(C1-C4-alkyl)2, the C1-C4-alkyl, C1-C4-haloalkyl, C1-C4-alkoxy, C1-C4-haloalkoXy, C1-C4-alkylthio groups and halogen atoms mentioned in detail for R1, especially chlorine, methyl, methoxy, ethoxy, difluoromethoxy, trifluoromethoxy;
X nitrogen or CR14 where R14 is hydrogen or alkyl, or CR14 forms together with CR3 a 4- to 5-membered alkylene or alkenylene ring in which, in each case, a methylene group can be replaced by oxygen or sulfur, Uv~U/ ~~~u~ CA 02201785 1997-04-03 such as -CHZ-CH2-0-, -CH=CH-O-, -CH2-CHZ-CH2-O-, -CH=CH-CH20-, in particular hydrogen, -CH2-CH2-O-, -CH(CH3)-CH(CH3)-O-, -C(CH3)=C(CH3)-O-, -CH=C(CH3)-O- Or -C(CH3)=C(CH3)-S;
R3 the hydrogen, hydroxyl, N(C1-C4-alkyl)2, C1-C4-alkyl, C1-C4-haloalkyl, C1-C4-alkoxy, C1-C4-haloalkoxy, C1-C4-alkyl-thio groups and halogen atoms mentioned for R1, especially chlorine, methyl, methoxy, ethoxy, difluoromethoxy, tri-fluoromethoxy or is linked to Ri4 as mentioned above to give a 5- or 6-membered ring;
R4 and RS phenyl or naphthyl, which can be substituted by one or more, eg. one to three, of the following radicals: halogen, vitro, cyano, hydroxyl, mercapto, amino, C1-C4-alkyl, C1-C4-haloalkyl, C1-C4-alkoxy, C1-C4-haloalkoxy, C1-C4-alkylthio, C1-C4-alkylamino, di-C1-C4-alkylamino, C1-C4-alkylcarbonyl, C1-C4-alkoxycarbonyl; phenyl or naphthyl, which are connected together in the ortho positions by a direct linkage, a methylene, ethylene or ethenylene group, an oxygen or sulfur atom or an SOZ, NH or N-alkyl group, or C3-C7-cycloalkyl;
R6 C1-C8-alkyl, C3-C6-alkenyl, C3-C6-alkynyl or C3-C8-cycloalkyl as mentioned above in particular, it being possible for these radicals in each case to be substituted one or more times by:
halogen, hydroxyl, vitro, cyano, C1-C4-alkoxy, C3-C6-alkenyl-oxy, C3-C6-alkynyloxy, C1-C4-alkylthio, C1-C4-haloalkoxy, C1-C4-alkylcarbonyl, hydroxycarbonyl, C1-C4-alkoxycarbonyl, C1-C4-alkylamino, di-C1-C4-alkylamino or unsubstituted or substituted phenyl or phenoxy, as mentioned above in particular;
phenyl or naphthyl, which can be substituted by one or more of. the following radicals: halogen, vitro, cyano, hydroxyl, amino, C1-C4-alkyl, C1-C4-haloalkyl, C1-C4-alkoxy, C1-C4-halo-alkoxy, phenoxy, C1-C4-alkylthio, C1-C4-akylamino [sic] or C1-C4-dialkylamino, as mentioned in particular for R~ and R4;
a five- or six-membered heteroaromatic moiety which contains one to three nitrogen atoms and/or one sulfur or oxygen atom and which can carry one to four halogen atoms and/or one or two of the following radicals: G1-C4-alkyl, C1-C4-haloalkyl, C1-Cq-alkoxy, C1-C4-haloalkoxy, C1-C4-alkylthio, phenyl, phenoxy or phenylcarbonyl, it being possible for. the phenyl radicals in turn to carry one to five halogen atoms and/or one to three of the following radicals: C1-C~-alkyl, C1-C4-haloalkyl, C1-C4-alkoxy, C1-C4-haloalkoxy and/or C1-C4-alkylthio, as mentioned for R4 in particular;

Y sulfur, oxygen or a single bond;
Z sulfur, oxygen, -SO-, -SOz- or a single bond.
Particularly preferred compounds of the formula I, both as pure enantiomers and pure diastereomers or as mixture thereof, are those in which the substituents have the following meanings:
R2 C1-Cq-alkyl, C1-C4-alkoxy X nitrogen or CR14, where R14 is hydrogen or alkyl, or CR14 forms together with CR3 a 4- or S-membered alkylene or alkenylene ring such as -CHZ-CHZ-CHZ-, -CH=CH-CH2-, in which in each case a methylene group can be replaced by oxygen or sulfur, such as -CHZ-CHZ-O-, -CH=CH-O-, -CHZ-CH2-CHZ-O-, -CH=CH-CHZO-, in particular hydrogen, -CHZ-CH2-O-, -CH(CH3)-GH(CH3)-O-, -C(CH3)=C(CH3)-O-, -CH=C(CH3)-O- or -C(CH3)=C(CH3)-S;
R3 the C1-C4-alkyl, C1-C4-alkoxy, C1-C4-alkylthio groups mentioned for R1, or is linked to R14 as mentioned above to give a 5- or 6-membered ring;
R4 and R5 phenyl (identical or different) which can be substituted by one or more, eg. one to three, of the following radicals: halogen, nitro, hydroxyl, C1-C4-alkyl, C1-C4-alkoxy, C1-C9-alkylthio or R4 and R5 are phenyl groups which are connected together in the ortho positions by a direct linkage, a methylene, ethylene or ethenylene group, an oxygen or sulfur atom or an SOy, NH or N-alkyl group; or R4 and R5 are C3-C7-cycloalkyl;
R6 C1-CB-alkyl, C3-C6-alkenyl or C3-Ce-cycloalkyl, it being possible for these radicals in each case to be substituted one or more times by: halogen, hydroxyl, nitro, cyano, C1-C4-alkoxy, C3-C6-alkenyloxy, C1-C4-alkylthio;

UUSU/ 4~.~ts1 CA 02201785 1997-04-03 phenyl or naphthyl, which can be substituted by one or more of the following radicals: halogen, nitro, cyano, hydroxyl, amino, C1-C4-alkyl, C1-C4-haloalkyl, C1-C4-alkoxy, C1-C9-halo-alkoxy, phenoxy, C1-C4-alkylthio, C1-C4-akylamino [sic] or C1-C4-dialkylamino;
a five- or six-membered heteroaromatic moiety which contains a nitrogen atom and/or a sulfur or oxygen atom and which can carry one to four halogen atoms and/or one or two of the following radicals: C1-C4-alkyl, C1-C4-haloalkyl, C1-C4-alkoxy, C1-C4-alkylthio, phenyl, phenoxy or phenylcarbonyl, it being possible for the phenyl radicals in turn to carry one to five halogen atoms and/or one to three of the following radicals:
C1-C4-alkyl, C1-C4-haloalkyl, C1-C4-alkoxy and/or C1-C4-alkyl-thio;
Y sulfur, oxygen or a single bond;
Z sulfur, oxygen, -SO-, -S02- or a single bond.
The compounds of the present invention provide a novel thera-peutic potential for the treatment of hypertension, pulmonary hy-pertension, myocardial infarct, angina pectoris, acute kidney failure, renal insufficiency, cerebral vasospasms, cerebral is-chemia, subarachnoid hemorrhages, migraine, asthma, atherosclero-sis, endotoxic shock, endotoxin-induced organ failure, intra-vascular coagulation, restenosis after angioplasty, benign pros-tate hyperplasia, or hypertension or kidney failure caused by is-chemia or intoxication.
The good effect of the compounds can be shown in the following tests:
Receptor binding studies Cloned human ETA receptor-expressing CHO cells and guinea pig cerebellar membranes with > 60 % ETB compared with ETA receptors were used for binding studies.
The ETA receptor-expressing CHO cells were grown in F12 medium containing 10 % fetal calf serum, 1 % glutamine, 100 U/ml peni-cillin and 0.2 % streptomycin (Gibco BRL, Gaithersburg, MD, USA).
After 48 h, the cells were washed with PBS and incubated with 0.05 % trypsin-containing PBS for 5 min. Neutralization was then carried out with F1z medium, and the cells were collected by cen-trifugation at 300 x g. To lyze the cells, the pellet was briefly washed with lysis buffer (5 mM Tris-HC1, pH 7.4 with 10 % gly-cerol) and then incubated at a concentration of 10~ cells/ml of lysis buffer at 4°C~for 30 min. The membranes were centrifuged at 20,000 x g for ZO min, and the pellet was stored in liquid ni-trogen.
Guinea pig~cerebella were homogenized in a Potter-Elvejhem homogenizes and [lacunas obtained by differential centrifugation at 1000 x g for 10 min and repeated centrifugation of the super-natant at 20,000 x g for 10 min.
Binding assays For the ETA and ETg receptor binding assay, the membranes were suspended in incubation buffer (50 mM Tris-HC1, pE 7.4 with 5 mM
MnClZ, 40 ~g/ml bacitracin and 0.2 % BSA) at a concentration of 50 ~g of protein per assay mixture and incubated with 25 pM
[i25=]-ETl (ETR receptor assay) or 25 pM [125Ij-R23 (ET$ receptor assay) in the presence and absence of test substance at 25'C. The nonspecific binding Was determined using 10-~ M ETl. After 30 min, the free and bound radioligand were separated by filtration through GF/B glass fiber filters (Whatman, England) on a Skatron cell collector (Skatron, Lier, Norway) and the filters were washed with ice-cold Tris-HCl buffer, pH 7.4 with 0.2 % BSA. The radioactivity collected on the filters was quantified using a Packard 2200 CA liquid scintillation counter.
Functional in vitro assay system to look for endothelia receptor (subtype A) antagonists This assay system is a functional, cell-based assay for endothe-lia receptors. «hen certain cells are stimulated with endothelia 1 (ETl) they show an increase in the intracellular calcium con-centration. This increase can be measured in intact cells loaded with calcium-sensitive dyes.
1-Fibroblasts which had been isolated from rats and in which an endogenous endothelia receptor of the A subtype had been detected were loaded with the fluorescent dye Fura 2-an as follows: after trypsinization, the cells were resuspended in buffer A (120 mM
NaCl, 5 mM RC1, I.S.mM MgCI2, 1 mM CaClZ, 25 mM BEPES, IO mM
glucose, pH 7.4).to a density of 2 x 106/ml and incubated with Fura 2-am (2 EcM), Pluronics F-127 (0.04 %) and DMSO (0.2 %) at 37~C in the dark for 30 min. The cells were then washed twice with buffer A and resuspended at 2 x 106/ml.
* trademark UU:.~Ui 4:a'ul CA 02201785 1997-04-03 The fluorescence signal from 2 x 105 cells per ml with Ex/Em 380/510 was recorded continuously at 30°C. The test substances and, after an incubation time of 3 min, ET1 [lacuna) to the cells, the maximum change in the fluorescence was determined. The response of the cells to ET1 without previous addition of a test substance was used as control and was set equal to 100 %.
Testing of ET antagonists in vivo Male SD rats weighting 250-300 g were anesthetized with amobarbi-tal, artifically ventilated, vagotomized and pithed. The carotid artery and jugular vein were cathetized [sic].
In control animals, intravenous administration of 1 ~g/kg ET1 led to a distinct rise in blood pressure which persisted for a lengthy period.
The test animals received an i.v. injection of the test compounds (1 ml/kg) 5 min before the administration of ET1. To determine the ET-antagonistic properties, the rise in blood pressure in the test animals was compared with that in the control animals.
Endothelia-1-induced sudden death in mice The principle of the test is the inhibition of the sudden heart death caused in mice by endothelia, which is probably induced by constriction of the coronary vessels, by pretreatment with endo-thelia receptor antagonists. Intravenous injection of 10 nmol/kg endothelia in a volume of 5 ml/kg of body weight results in death of the animals within a few minutes.
The lethal endothelia-1 dose is checked in each case on a small group of animals. If the test substance is administered intra-venously, the endothelia-1 injection which was lethal in the ref-erence group usually takes place 5 min thereafter. With other modes of administration, the times before administration are ex-tended, where appropriate up to several hours.
The survival rate is recorded, and effective doses which protect 50 % of the animals (ED 50) from endothelia-induced heart death for 24 h or longer are determined.
Functional test on vessels for endothelia receptor antagonists Segments of rabbit aorta are, after an initial tension of 2 g and a relaxation time of 1 h in Krebs-Henseleit solution at 37°C and pH 7.3-7.4, first induced to contract with K+. After washing out, an endothelia dose-effect plot up to the maximum is constructed.

Potential endothelia antagonists are administered to other prep-arations of the same vessel 15 min before starting the endothelia dose-effect plot. The effects of the endothelia are calibrated as a % of the K+-induced contraction. Effective endothelia antagon-10 fists result in a shift to the right in the endothelia dose-effect plot.
The compounds according to the invention can be administered orally or parenterally (subcutaneously, intravenously, intra-15 muscularly, intraperotoneally) in a conventional way. Administra-tion can also take place with vapors or sprays through the naso-pharyngeal space.
The dosage depends on the age, condition and weight of the 20 patient and on the mode of administration. The daily dose of ac-tive substance is, as a rule, about 0.5-50 mg/kg of body weight, on oral administration and about 0.1-10 mg/kg of body weight on parenteral administration.
The novel compounds can be used in conventional solid or liquid pharmaceutical forms, eg. as uncoated or (film-)coated tablets, capsules, powders, granules, suppositories, solutions, ointments, creams or sprays. These are produced in a conventional way. The active substances can for this purpose be processed with conven-tional pharmaceutical aids such as tablet binders, fillers, pre-servatives, tablet disintegrants, flow regulators, plasticizers, wetting agents, dispersants, emulsifiers, solvents, release-slowing agents, antioxidants and/or propellent gases (cf. H.
Sucker.et al.: Pharmazeutische Technologie, Thieme-Verlag, Stutt-gart, 1991). The administration forms obtained in this way normally contain from 0.1 to 90 % by weight of the active substance.
Synthesis examples Example 1 Methyl 2-hydroxy-3-methoxy-3,3-diphenylpropionate 5 g (19.6 mmol) of methyl 3,3-Biphenyl-2,3-epoxypropionate were dissolved in 50 roil of absolute methanol and, at 0°C, 0.1 mI of boron trifluoride etherate was added. The mixture was stirred at 0°C for 2 h and at room temperature for a further 1~ h. The sol-vent was distilled out, the residue was taken up in ethyl acet-ate, washed with sodium bicarbonate solution and water and dried over magnesium sulfate. After removal of the solvent by distilla-tion there remained 5.5 g (88 %) of a pale yellow oil.
Example 2 Methyl 2-hydroxy-3-phenoxy-3,3-diphenylpropionate 5 g (19.6 mmol) of methyl 3,3-diphenyl-2,3-epoxypropionate and 5.6 g (60 mmol) of phenol were heated together at 100°C for 6 h.
Removal of the excess phenol by distillation under high vacuum and purification of the residue by chromatography on silica gel with hexane/ethyl acetate mixtures resulted in 4.9 g (77 %) of a pale yellow oil.
Example 3 Methyl 2-(4,6-dimethoxy-pyrimidin-2-yloxy)-3-methoxy-3,3-diphenylpropionate 2.86 g (10 mmol) of methyl 2-hydroxy-3-methoxy-3,3-diphenyl-propionate were dissolved in 40 ml of dimethylformamide, and 0.3 g (12 mmol) of sodium hydride was added. The mixture was stirred for 1 h and then 2.2 g (10 mmol) of 4,6-dimethoxy-2-meth-ylsulfonylpyrimidine were added. After stirring at room tempera-ture for 24 h, cautious hydrolysis was carried out with 10 ml of water, the pH was adjusted to 5 with acetic acid, and the solvent was removed by distillation under high vacuum. The residue was taken up in 100 ml of ethyl acetate, washed with water and dried over magnesium sulfate, and the solvent was distilled out. The residue was mixed with 10 ml of ether, and the resulting precipitate was filtered off with suction. After drying, 3.48 g (82 %) of a white powder remained.
Melting point 81°C.
Example 4 2-(4,6-Dimethoxy-pyrimidin-2-yloxy)-3-methoxy-3,3-diphenyl-propionic acid 2.12 g (5 mmol) of methyl 2-(4,6-dimethoxy-pyrimidin-2-yl-oxy)-3-methoxy-3,3-diphenylpropionate were dissolved in 50 ml of dioxane, 10 ml of 1 N KOH solution were added, and the mixture was stirred at 100°C for 3 h. The solution was diluted with 300 ml of water and extracted with ethyl acetate to remove unreacted ester. The aqueous phase was then adjusted to pH 1-2 with dilute hydrochloric acid and extracted with ethyl acetate. After drying over magnesium sulfate and removal of the solvent by distilla-tion, the residue was mixed with an ether/hexane mixture, and the precipitate which formed was filtered off with suction. After drying, 1.85 g (90 %) of a white powder remained.
Melting point 167°C
Example 5 2-(4,6-Dimethoxy-2-pyrimidinyloxy)-3 -methoxy-3,3-diphenyl sodium [sic] propionate 1.68 g (4 mmol) of 2-(4,6-dimethoxy-2-pyrimidinyloxy)-3-methoxy-3,3-diphenylpropionic acid are dissolved in 4 ml of 1N
NaOH + 100 ml of water. The solution is freeze-dried, and the sodium salt of the carboxylic acid used is obtained quantitatively.
10 g (34.9 mmol) of methyl 2-hydroxy-3-methoxy-3,3-diphenylpro-pionate were dissolved in 50 ml each of methanol and glacial acetic acid, 1 ml of Ru0(OH)Z in dioxane was added, and hydrogena-tion was carried out with HZ in an autoclave at 100°C under 100 bar for 30 h. The catalyst was filtered off, the mixture was concentrated, mixed with ether and washed with NaCl solution, and the organic phase was dried and concentrated. 10,1 g of methyl 3,3-dicyclohexyl-2-hydroxy-3-methoxypropionate were obtained as an oil.
Example 7 Methyl 2-[(4,6-dimethoxy-pyrimidin-2-yl)thio]-3-methoxy-3, 3-diphenylpropionate [sic]
7.16 g (25 mmol) of methyl 2-hydroxy-3-methoxy-3,3-diphenylpro pinnate were dissolved in 50 ml of dichloromethane, 3 g (30 mmol) of triethylamine were added, and 3.2 g (28 mmol) of methane-sulfonyl chloride were added dropwise while stirring. The mixture was stirred at room temperature for 2 h, washed with water, dried over magnesium sulfate and concentrated under reduced pressure.
The residue was taken up in DMF and added dropwise at 0°C to a suspension of 12.9 g (75 mmol) of 4,6-dimethoxypyrimidine-2-thiol and 8.4 g (100 mmol) of sodium bicarbonate in 100 ml of DMF.
After stirring at room temperature for 2 h and at 60°C for a further 2 h, the mixture was poured into 1 liter of ice-water, and the resulting precipitate was filtered off with suction.
After drying, 3.19 g (29 %) of a white powder remained.

Uu~U/ 4"~1 CA 02201785 1997-04-03 Example 8 Methyl 2-hydroxy-3,3-diphenylbutyrate 1.5 g (5.9 mmol) of methyl 3,3-diphenyl-2,3-epoxypropionate dis-solved in 10 ml of absolute ether were added dropwise to a cup-rate solution which had been prepared from 635 mg (7 mmol) of copper(I) cyanide dissolved in 10 ml of absolute ether and 8.14 ml (13 mmol) of a 1.6 normal methyllithium solution and had been cooled to -78°C. The solution was stirred at -78°C for 1 h and then allowed to warm to room temperature. It was subsequently diluted with 100 ml of ether and 100 ml of water, and the ether phase was washed with dilute citric acid and with sodium bicar-bonate solution and dried over magnesium sulfate. The crude prod-uct was purified by chromatography on silica gel with cyclohex-ane/ethyl acetate mixtures to result in 250 mg (16 %) of a pale yellow oil.
Example 9 2-Hydroxy-3-methoxy-3,3-diphenylpropionic acid 91.11 g (0.5 mol) of benzophenone and 45.92 g (0.85 mol) of so-dium methoxide were suspended in 150 ml of methyl tert-butyl ether (MTB) at room temperature. After cooling to -10°C, 92.24 g (0.85 mol) of methyl chloroacetate were added in such a way that the internal temperature rose to 40°C while continuing to cool in a bath at -10°C. The mixture was then stirred without cooling at the autogenous temperature for one hour. After addition of 250 ml of water and brief stirring, the aqueous phase was separated off.
The MTB phase was washed with 250 ml of dilute sodium chloride solution. After the solvent had been changed to methanol (250 ml), a solution of 1 g of p-toluenesulfonic acid in 10 ml of methanol was added at room temperature. The mixture was stirred at autogenous temperature for one hour and then heated to reflux.
While distilling out the methanol, 400 g of a 10 % strength sodium hydroxide solution was added dropwise, and finally 60 ml of water were added. The methanol was distilled out until the bottom temperature reached 97°C. After cooling to 55°C, 190 ml of MTB were added and the mixture was acidified to pH 2 with about 77 ml of concentrated HC1. After cooling to room temperature, the aqueous phase was separated off and the organic phase was concen-trated by distilling out 60 ml of MtB [sic]. The product was cry-stallized by adding 500 ml of heptane and slowly cooling to room temperature. The coarsely crystalline solid was filtered off with suction, washed with heptane and dried to constant weight in a vacuum oven at 40°C.
Yield: 108.9 g (80 %), HPLC > 99.5 % areao UuSU/ 4~i~s1 CA 02201785 1997-04-03 Example 10 S-2-Hydroxy-3-methoxy-3,3-diphenylpropionic acid (racemate resolution with L-proline methyl ester) 148.8 g of a 30 % strength methanolic sodium methanolate solution (0.826 mol) were added dropwise to 240 g of a 57 % strength me-thanolic L-proline methyl ester hydrochloride solution (0.826 mol) at room temperature, and 2.4 1 of MTB and 225 g (0.826 mol) of 2-hydroxy-3-methoxy-3,3-diphenylpropionic acid were added. After 2680 ml of MTB/methanol mixture had been dis-tilled out with simultaneous dropwise addition of 2.4 1 of MTB, the mixture was slowly cooled to room temperature, the crystals (R-2-hydroxy-3-methoxy-3,3-diphenylpropionic acid x L-proline methyl ester) were filtered off with suction, and the solid was washed With 150 ml of MTB. The filtrate was concentrated by dis-tilling out 1.5 1 of MTB, and 1.0 1 of water was added. The pH
was adjusted to 1.2 with concentrated hydrochloric acid at room temperature and, after stirring and phase separation, the aqueous phase was separated off and extracted with 0.4 1 of MTB. The com-bined organic phases were extracted with 0.4 1 of water. The residue after the MTB had been stripped off was dissolved in 650 ml of toluene under reflux, and the product was crystallized by seeding and slow cooling. Filtration with suction, washing with toluene and drying in a vacuum oven resulted in 78.7 g of S-2-hydroxy-3-methoxy-3,3-diphenylpropionic acid (yield 35 %
based on the racemate).
Chiral HPLC: 100 % pure HPLC: 99.8 %
Example 11 S-2-Hydroxy-3-methoxy-3,3-diphenylpropionic acid (racemate resolution with (S)-1-(4-nitrophenyl)ethylamine) 30.5 g.(0.184 mol) of (S)-1-(4-nitrophenyl)ethylamine were added to 100 g (0.368 mol) of 2-hydroxy-3-methoxy-3,3-diphenylpropionic acid in 750 ml of acetone and 750 ml of MTB under reflux, the mixture was seeded, boiled under reflux for one hour and slowly cooled to room temperature for crystallization. The crystals (S-2-hydroxy-3-methoxy-3,3-diphenylpropionic acid x (S)-1-(4-ni-trophenyl)ethylamine) were filtered off with suction and washed with MTB. The residue was suspended in 500 ml of water and 350 ml of MTB and then the pH was adjusted to 1.2 with concentrated hy-drochloric acid at room temperature, and, after stirring and phase separation, the aqueous phase was separated off and ex-tracted with 150 ml of MTB. The combined organic phases were ex-tracted with 100 ml of water. 370 ml of MTB were distilled out and then 390 ml of n-heptane were added under reflux, and the Uu~Ui ~~avt CA 02201785 1997-04-03 mixture was slowly cooled to room temperature while the product crystallized. Filtration with suction, washing with n-heptane and drying in a vacuum oven resulted in 35.0 g of S-2-hydroxy-3-me-thoxy-3,3-diphenylpropionic acid (yield 35 % based on the race-s mate).
Chiral HPLC: 100 % pure HPLC: 99.8 %
Example 12 10 Benzyl 3-methoxy-2-(4-methoxy-6,7-dihydro-5H-cyclopentapyrimi-din-2-yloxy)-3,3-diphenylpropionate 24.48 g (90 mmol) of 3-methoxy-3,3-diphenyl-2-hydroxypropionic acid were dissolved in 150 ml of DMF, and 13.7 g (99 mmol) of 15 potassium carbonate were added. The suspension was stirred at room temperature for 30 min. Then 10.7 ml (90 mmol) of benzyl bromide were added dropwise over the course of 5 min, and the mixture was stirred for 1 h, during which the temperature rose to 32°C.
To this mixture were successively added 24.84 g (180 mmol) of KzC03 and 20.52 g (90 mmol) of 2-methanesulfonyl-4-methoxy-6,7-dihydro-5H-cyclopentapyridine [sic], and the mixture was stirred at 80°C for 3 h.
For workup, the contents of the flask were diluted with about 600 ml of H20 and cautiously acidified with concentrated HC1, and 250 ml of ethyl acetate were added. 31.4 g of pure product pre-cipitated and were filtered off.
The ethyl acetate phase was separated from the mother liquor, the aqueous phase was extracted again with ethyl acetate, and the combined organic phases were concentrated. The oily residue (19 g).was purified by chromatography (cyclohexane/ethyl acet-ate = 9/1) to result in a further 10.5 g of pure product.
Total yield: 41.9 g (82.2 mmol) ~-- 91 %
Melting point 143-147°C
MS: MH+ = 511 Example 13 3-Methoxy-2-(4-inethoxy-(6,7-dihydro-5H-cyclopentapyrimidin-2-yl-oxy)-3,3-diphenylpropionic [sic] acid 40 g (78.4 mmol) of benzyl 3-methoxy-2-(4-methoxy-6,7-di-hydro-5H-cyclopentapyrimidin-2-yloxy)-3,3-diphenylpropionate were dissolved in 400 ml of ethyl acetate/methanol (4:1), about 500 mg Uu:aU! 4:~iu1 CA 02201785 1997-04-03 of palladium on active carbon (10 %) were added, and the mixture was exposed to a hydrogen atmosphere until no further gas was taken up. The catalyst was filtered off, the solution was evaporated, and the residue was crystallized from ether.
Example 14 Ethyl 2S-3,3-diphenyloxirane-2-carboxylate 2.57 g (10.2 mmol) of ethyl 3,3-diphenylacrylate and 464 mg of 4-phenylpyridine N-oxide were dissolved in 24 ml of methylene chloride, and 432 mg (6.5 mol%) of (5,5)-(+)-N,N'-bis(3,5-di-tert-butylsalicylidene)-1,2-cyclohexanediaminomanganese(III) chloride were added. While cooling in ice, 6.4 ml of a 12 %
strength sodium hypochloride [sic] solution were added, and the mixture was stirred while cooling in ice for 30 min and at room temperature overnight. The solution was diluted to 200 ml with water, extracted with ether, dried and evaporated. 2.85 g of a colorless oil were obtained. Purification by NPLC [sic] (cyclo-hexane:ethyl acetate = 9:1) resulted in 1.12 g of oil with an enantiomer ratio of about 8:1 in favor of the S configuration.
1H-NMR [CDC13], b = 1.0 (t, 3H); 3.9 (m, 3H); 7.3 (m, lOH) Example 15 2-Methylsulfonyl-6,7-dihydro-5H-cyclopentapyrimidin-4-of [sic]
46.9 g (330 mmol) of methyl cyclopentanone-2-carboxylate and 53.5 g~(192 mmol) of 5-methylisothiourea [sic] sulfate were suc-cessively added to 29.6 g (528 mmol) of ROH in 396 ml of meth-anol, and the mixture Was stirred at room temperature overnight, acidified with 1N hydrochloric acid and diluted with water. The crystals which separated out were filtered off with suction and dried. 20 g of crystals were obtained.
Example 16 sulfanyl 4-Chloro-2-methyl-6,7-dihydro-5H-cyclopentapyrimidine [sic]
255 ml of phosphorus oxychloride were added to 20 g (110 mmol) [lacuna], and the mixture was stirred at 80°C for 3 hours. Phos-phorus oxychloride was evaporated off, ice was added to the resi-due, and the crystals which separated out were filtered off with suction. 18.5 g of a brownish solid were obtained.

UUSU/ 45~tf1 CA 02201785 1997-04-03 ' 27 Example 17 4-Methoxy-2-methylsulfonyl-6,7-dihydro-5H-cyclopentapyrimidine [sic]
18.05 g (90 mmol) of 4-chloro-2-methylsulfonyl-6,7-di-hydro-5H-cyclopentapyrimidine [sic] were dissolved in 200 ml of methanol. At 45°C, 16.7 g of sodium methoxide (as 30 % strength solutions [sic] in methanol) were added dropwise, and the mixture was stirred for 2 hours. The solution was evaporated, taken up in ethyl acetate and acidified with dilute hydrochloric acid, and the ethyl acetate extract was evaporated. 15.5 g of an oil re-mained.
1H-NMR [DMSO], 8 = 2.1 (quintet, 2H); 2.5 (s, 3H);
2.8 (dt, 4H); 3.9 (s, 3H) ppm Example 18 2-Methylsulfonyl-4-methoxy-6,7-dihydro-5H-cyclopentopyrimidine [sic]
15 g (76.2 mmol) of 4-methoxy-2-methylsulfonyl-6,7-dihydro-5H-cyclopentapyrimidine [sic] were dissolved in 160 ml of glacial acetic acid/methylene chloride (1:1), and 1.3 g of sodium tung-state were added. At 35°C, 17.5 ml (170 inl [sic]) of a 30 %
strength H202 solution were added dropwise. The mixture was then diluted with 500 ml of water and 100 ml of methylene chloride, and the organic phase was separated off, dried and evaporated. 14 g of oil remained and were crystallized from ether.
iH-NMR [CDC13], b = 2.2 (quintet, 2H); 3.0 (dt., 4H);
3.3 (s, 3H); 4.1 (s, 3H) ppm Example 19 1-Benzenesulfonyl-3-(4,6-dimethoxy-2-pyrimidinyloxy)-4-methoxy-4,4-diphenyl-2-butanone 0.37 g (2.4 mmol) of phenyl methane [sic] sulfone were dissolved in 10 ml of dry THF and then, at -?0°C, 2 eq. of butyllithium (2.94 ml; 1.6 molar solution in hexane) were added dropwise.
After 1 h at -70°C, 1 g (2.4 mmol) of methyl 2-(4,6-dime-thoxy-2-pyrimidinyloxy)-3-methoxy-3,3-diphenylpropynoate.[sic]
dissolved in 5 ml of THF was added dropwise. The reaction mixture was then stirred at -70°C for 1 h and at -10°C for 1 h and then warmed to room temperature.

UUSU/ 451ti1 CA 02201785 1997-04-03 For workup, about 10 ml of saturated NH4C1 solution were added dropwise, thorough extraction with ethyl acetate was carried out, and the combined organic phases [lacuna) with-saturated N-C1 [sic] solution and dried over Na2S04. The residue obtained after drying and concentration was purified by chromatography on silica gel (n-heptane/ethyl acetate 15 % -~ 30 %) and subsequently MPLC
on RP silica gel (acetonitrile/H20 + TFA); 0.3 g of a white amorphous powder was obtained as product.
Example 20 3,3-Diphenyloxiram-2-carbonitrile [sic]
3.1 g (54.9 mmol) of sodium methoxide were suspended in 20 ml of dry THF and then, at -10°C, a mixture of 5 g (27.4 mmol) of benzo-phenone and 4.2 g (54.9 mmol) of chloroacetonitrile was added dropwise.
The reaction mixture was stirred at -10°C for about 2 h, then poured into water and extracted several times with ethyl acetate.
The combined organic phases were dried over Na2S04 and concen-trated, and the residue was purified by chromatography on silica gel (n- heptane/ethyl acetate).
Yield: 1.2 g (20 %) 1H-NMR [CDC13], b = 3.9 (s, 1H); 7.4-7.5 (m, 10 H) ppm Example 21 2-Hydroxy-3-methoxy-3,3-diphenylpropionitrile 6.5 [lacuna] (29.4 mmol) of 3,3-diphenyloxirane-2-carbonitrile were dissolved in 60 ml of methanol and, at 0°C, about 2 ml of boron trifluoride etherate solution were added. The mixture was stirred further at 0°C for 1 h and then at room temperature over-night. For workup it was diluted with diethyl ether and washed with saturated NaCl solution, and the organic phase was dried over Na2S04 and concentrated. The residue comprised 7.3 g of a white amorphous powder which was used directly in the subsequent reactions.
1H-NMR [CDC13], 8 = 2.95 (broad s, OH), 3.15 (s, 3H), 5.3 (s, 1H), 7.3-7.5 (m, 10) ppm UUSU/ 45~tf1 CA 02201785 1997-04-03 Example 22 2-(4,6-Dimethoxy-2-pyrimidinyloxy)-3-methoxy-3,3-diphenylpro-pionitrile 7.3 g (28.8 mmol) of 2-hydroxy-3-methoxy-3,3-diphenylpropio-nitrile were dissolved in 90 ml of DMF, and 4 g (28.8 mmol) of KZC03 and 6.3 g (28 mmol) of 2-methanesulfonyl-4,6-dimethoxypy-rimidine were added. The mixture was stirred at room temperature for about 12 h, then poured into water and extracted with ethyl acetate. The combined organic phases were washed again with H20, dried and concentrated. The residue obtained in this way was then purified by chromatography on silica gel (n-hepane/ethyl acet-ate).
Yield: 6.9 g of white amorphous powder FAB-MS: 392 (M+H+) 1H-NMR [CDC13], b = 3.3 (s, 3H); 4.95 (s, 6H), 5.85 (s, 1H);
6.3 (s, 1H); 7.3-7.5 (m, lOH) ppm Example 23 5-[2-(4,6-Di.methoxy-2-pyrimidinyloxy)-3-methoxy-3,3-diphenyl)-propyl]-1H-tetrazole [sic]
0.5 g (1.3 mmol) of nitrile was dissolved in 10 ml of toluene, and 85 mg (1.3 mmol) of NaN3 and 460 mg (1.4 mmol) of Bu3SnC1 were successively added, and then the mixture was refluxed for about 40 h. Cooling was followed by dilution with ethyl acetate and washing with 10 % aqueous KF solution and with NaCl solution.
After drying over MgS04 and concentration there remained 1.0 g of a yellow oil, which was purified by chromatography on silica gel (n-heptane/ethyl acetate).
Concentration of the fractions resulted in 60 mg of the 1H-tetra zole and 110 mg of the 1-methyltetrazole, each as amorphous white solids.
5-[2-(4,6-Dimethoxy-2-pyrimidinyloxy)-3-methoxy-3,3-diphenyl)-propyl]-1H-tetrazole [sic]
Electrospray-MS: 435 (M+H+) 1H-NMR (CDC13):
$ (ppm) 3.28 (s, 3H), 3.85 (s, 6H), 5.75 (s, 1H); 7.25-7.40 (m, lOH), 7.50 (s, 1H).

5-[2-(4,6-Dimethoxy-2-pyrimidinyloxy)-3-methoxy-3,3-diphenyl)-propyl)-1-methyltetrazole [sic]
Electrospray-MS; 471 (M+H+) 5 1H-NMR (CDC13):
b (ppm) 3.0 (s, 3H), 3.35 (s, 3H9 [sic], 3.80 (s, 6H), 5.75 (s, 1H), 7.30-7.40 (m, 11H).
Example 24 10 2-(4,6-Dimethoxy-2-pyrimidinyloxy)-3-methylsulfinyl-3,3-diphenylpropionic acid 1.2 g (2.9 mmol) of 2-(4,6-dimethoxy-2-pyrimidinyloxy)-3-methylsulfonyl-3,3-diphenyl-15 propionic [sic] acid were introduced into 15 ml of glacial acetic acid at 0°C and 294 ~1 of 30 % strength HZ02 were added dropwise.
The mixture was stirred at room temperature overnight, poured into water, extracted with CHzCl2 and washed with sodium thiosul-fate solution and brine. After drying, 1 g of substance was iso-20 lated as a white foam.
Example 25 2-(4,6-Dimethoxy-2-pyrimidinyloxy)-3-methylsulfonyl-3,3-diphenylpropionic acid 0.6 g (1.45 mmol) of 2-(4,6-dimethoxy-2-pyrimidinyloxy)-3-methyl-sulfonyl-3,3-diphenylpropionic [sic] acid was introduced into 15 ml of glacial acetic acid at room temperature, and 294 ~,1 of 30 %
strength H202 were added dropwise. The mixture was stirred at room temperature overnight, heated at 50°C for a further 3 h, poured into water and washed with sodium thiosulfate solution and brine.
After drying, 400 mg were isolated as a white solid.
The compounds listed in Table 1 [sic] can be prepared in a simi-lar way.

,.
d E

v o ~

N O O O O O vaO O O O O O O O

O O O O O O O v~O O O O O O

M M

x x U U
. .
.

. .
U U U U x x U U U

C U U U U U U

M
x U
~

o~w rJv a~ o~a~a~a a a~ a ~ x ~ ~ w a~0 0 0 0 0 0 0 0 0 o z o 0 0 U U U ~ U

~ U U U
~

O M U U N N N
x3 N N
U

U O O O O O

N T N N N N N _ If1 x ~. x x x x x T T T
.r a ~ U V U U U

p; n: ~.,~, U _ , '= N T ~ '=N N N N N

~ ~ ~ ~ W ~ ~ U U U U U c a c ~o PG

T T T T T >,T T T T T T T T
C C C C C C C C C C C C

~ C C .~CS ~ S ~ t .C ~ t .C ,ts S ~C

L~,f~,. O,OwCn Pw~ A.Cw Gni~0, O.~Ar C, ~ ~c x x x x x x x x x x ~ x ~xo 0 0 0 0 0 0 0 0 0 0 0 0 0 .rN M ~ V1~O t~00 O O O O O O O O O

~ .-.a~ .-rN N N N N N N N N
I I I I I I I I

I 1 I I ~.~....,...~...~. .~.~
,~ .......

U

M

N O O O O O O O O O O O O O , O O O O O O O O

O O O O O O O O O O O O O O O O O O O O O O

U

, U x U

x x x o x x x x x x x x x x x x ~ x x x x x x ~CU U ~ U U U U U U U U V V U U V U U U U U U

U

O , a v a~w o~a a~a a~ a a~a~a~ O a~a~ a~a a~ a ~ O O O O O O O O O O O O O O O O O O O O

a a a~w v a a _ a a a~ a a a a w a s~ a~asa~ w N ~ ~ ~ ~ ~ ~ ~ W
cxO O O O O O O O O O O O O O O O O O O O O O

N U
' x .N.

U a r, c N x -' x v N ~~'1s ~,,C ~ T
>' _a,a, , a _a,y ~ N x U 5C E .Ga c c T s a'n n. U U oT"x o~, a N U ci~O ~
aa C~~ U ~ o ~ s s ~
o 0 0 ,~M.,~ U N ? .; ~ ~ w N
~ ~ ~ ~,~,x x o o ~, ,~Q, i~rO, U U U ~ ~ x x U et ~ 'ctM

T 7,T T T T T T T T T T T T T T T T T >.T T
v~c C c c C C C C C C c C c C c c C c c C c c .'es ~ .~es s s s s ~ s .c.~cs s s .~.e s s .~ s a4C. a,a.o.a, a,a,a, a.cLc~.a.o,a.a. a,o~a. w a.A, o.

x x x x x x x x x x x x x x x x ~ x x x x m ~ 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Ov O ~ N M ~ V1v0 h o0Ov O -~N t~1ctV WO t~o0Cv O
p ,1 ,-,..1~ .-i.-r.~ N N N N N N N N N N
N N N N N N N N N N N N N N N N

.~,~ s U

o_ c;.

O O O O O O O O O O O O O O O O O

N O O O O O

O O O O O O O O O O O O O O O O O

O O O cnO

U

x ~ U U U U U U U U U

~'CU U U U U U V U U U U ~

U

O

v a~ a a~a~ a a a~ v v a~a~a~ a a a~ a~a~a w ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ W

L O O O O O O O O O O

AG O O O O O O O O O O O

a~a a a~a~ w a~a~ a~ a o~a~v a~a~a~d w a a _ a ~ ~ ~ ~ ~ ~ ~ W

~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ O

N O O O O O O O O O O O O O O O O O O

rs:O O O

T
C

_ T

C ~ .~ ~.N C C C

t ~ T

~

>, T ~ y t T d d d ~'O T ~ N T T d'O O O

C C _ _ ~ ~ N y O E T N C O ~ 4 ~ O~
C , T T C C C y y p ~
. . "

t .G ~ ~ N Q.E O E.. ~ y C~CA~ Q.N N V1(V

. x o 0 0 0 ~, ~ , ~ co~ ~ ~ ~ z C

U m w w U Z x ~ v ~r V CC w ~ ~ w .~

,o N M ~ d'et M N M M M ~ N M ~!N N M d'V N N d' p(, ~.

T T T T T T T T T T T T T T T T T T T T T T
C C C C C C

~' C C G C C C C C C C C C C C C C

~ ~ t ~ t L ~ L C L t ~ t L t t t s s ~ . . . . P A4 O p 0. I~G4C1,P, G~P.P..Q,Ow C C C

~Y.,OwCY G,P.Q. ArQ.A4 r . , x x x acx m x x x x x x x x x x x x x x x x 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0.0 0 0 0 .rN M ~ ~ 'Ot~ 00O~O -iN
~ ' d ~ 'ct'etetV1 V1V'1 M M M M M M M M N C ~ ~ ~ N N N N N N N N
N N N N N

p N N N N N N N N
..

..
U ~ "
v'~.
E
' ,r c .;
.-. o p. M ~
y a N O O O O O O O O O O O O O O O O cnO O O

O O O O O O O O O O O O O O cnO O O O O

U

U x U

'" U

x x x x x x x ~ x ~ x ~ x x x x x x x x ?CU U U U U U U N U x U x U U U V U V U U

V x U

O

O U

, O

a~ a a a a~d a a~ a a~ a~a a~a~a a O O O O O O O O O O O O O O O O O

o~ a a~ a~a~a~a~ a~a d m a~a~ a a~ a~a~a~ v O O O O O O O O O O O O O O

O O O O O O

>, N

C
N

t O

C

7, t N
E

O
X Q a O_ t s t ~ L G

_ .t t t L T ~ t O O t . ~ t y ~ ~ .
N

, N N ~ ~ r N N ~,ArN ~ t_~ ~ N N
, ~ ~ ~
d~.V

PGM ~ ~ ~ ~ W ~ ~ C C W
,~'.

T
C

N
t T Q
N

C C

t 7,7, ~, T ~.

N >.i, C C C ~ T t S .t~ C
~

T ~,C CL,C4~ ~ ~ ~ .~ . C C C
t a, C s E
' ~ a s p O a w ; a, a o~O O o , s ' t n. , , , m,~ N ~''~ w w a~ a~A A w w w U ~ ~ ~ ~ U U Z Z U ti, rz,~ ~ ~ ~ V
.

s , , , , , , , , , , , , , , , p, ~ ~ ~ ~ ~ ~ ti'M M ~t ~ M N N N N M M 4 a x x ~ x x x m x x x x a~x x x x x x x x x o 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 .rN M ~ V1~D t~00 OvO -~ N
_ ~ ~ ~O ~DI~l~ t~

N N N N ~ ~ ~Ov0~D ~Dv0~D D N N N N N
N N N N N N

N N N N

,..
c. c.

E .. E

o E a~

.b p U
~

..r ~ 00 ' c ~0 . ' r. r, , O O O O O O O O O O O O O

N O O O O O O O O O

O O O O O O O O O O O O O

?~O cnO O O O O O O

~ U N N

U U N x U x ~ ~ N N v v N N x ~ x x x x U ~i V U U ~ x U U x x " ~~a U U x ~ U U U U U ~ V U x ~ U V U

?CU Z x j M ~ x ~ ~ r" , x x v M ~ ~ ~

x ~ ; N N U U
V U x x O O V ~ U O O O ~ V V C

x 5 O M O Z p a~ U U

, w ~ o o z o v v ~ o s o o 0 0 0 0 0 ~ 0 0 0 0 0 0 ~ ~ ~ o o ~ w o c d j y ~ i T T T T 7.T T T T T T ?.T

C , , , . ~ .G.C ~ ~ t .Ct S S t ~ y C N

. C N N ~ N ~ ~ N ~ ~ N N

N N L CS,N N m N N ~ N ~ ~ ~ ~ x ~

w c ~ ~ ~ ~ ~

c c s s n. a.

c s s s _ _ ~ a E E

> O ~ T T T T T T T T 'C'=T T T 7.T

T T , ~ c c A O c c c c c c c a ~ c c c c c c w c c w ~ a~a~~ ~ a a~a~ a~a~a a ~ u"a a a a~s a~ c v a~ e s s t . .c.ct .ct s s ; .e .nt . w ~

s . , a M w w o. a,a.a, a.~ v a, w a. a.

p;a. a,a,a w . M

~ o 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 x N M ~ V1~O h 00OvO ~ N M ~

~ 0 000000 0000QO 000000Ov OvOv C~O~

N N N N N N N N N N N N N N N N N N N

p N N .:

U

a 13. V

M

O O viO O O O O v~O O O O O cnO O

N O O O v~ vi O O O O cn O O O cn O O O O O O

?~ O O O O O ~n rn U

x x ~ x x N x x x x x x x x x x x x ?C U U U ~ U U U Z U U U U U V U U Z Z Z

U U x U

N
x x x x x x x M M w M x x x M M
~

U U U U U U w w U U U U x ~ W ~ ~ O O O O O U U O ~ U O O O O U U

O O

M M M M M M - M M M M M M M M M M
x x x x x x x x x x x x x x M x x U U U U U U w U U ~ U U U U U U U

~ O O O O O O O U O O O O O O O O O O

O O

a, M

C

T
a a a, T T T T ivT T T T T ?vT ~ d'w 7~T T N i,T

t .~ t t t t t t t t t t T p,~ O .~.rS t ~
a N ~ ~ N N N ~ ~ N ~ N t O O,~ N N N " O

~ ~ ~ ~ ~ ~ ~ ~ ~ ~ _ 0 ~ tiW
4th Qi ~ ~ r r . r , .

7, C

N
t a a c a .e j,T T , O ~ y C

N
S s ~

' T N T O
t O p d'7CL X '' X p . . T O C. O
O O

a v ''p E y t o 'C

~ ' ~ x H

U U a h.U c~ w v a~n~
z er~s s s T T y ~ e~t I I I t t t t 1 I I .~1 I
t t t U U G P O CL N M ~ f3.C1.C.P. N M ~ P.,N M

LY,P.G~,Or . r .

x M M x U

N v, ' 'T'.MU ,~,~U N
LM' ~ x x . , a ~ ;;o ~ , ~

x x N .., 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 ~ 0 0 0 0 0 0 a~

.-rN M ~ V1~O ~ 00C~O eHN M ti'V'7~O

~ O O O O O O O O O O M M M M M M M

~
z N N N N N M M M M M M M M M I I I I 1 I 1 I
I 1 1 1 I I I I I I I I I I M~/I-rrr-mw r-~..~~.r r.m r.-n.~r..~w ...w.r..mrrw rrr.wrw~

U

a 0.

N O O O O O O O O cn~nO O O O O O O O cnO O O

cn O O ~n O O O w v~O O O O O O O O O O O cn O

x , x x x x x x x x Z x x x x x x N U Z U U U U U U U U U U U U U U

x x U U

~CU U U

O O

i M M M M M M M M M M M M M M M M M ~c M x U x x x x x x x x x x x w U
U x U U V U U U U U U U U w w U x U
c~:O U O O O O O O O O O O O U U O U O

M M M M M M M M M M T M M M M M M M M
N x M x x x x x x x x x = x x x M x x x x x U x U U U U U U U U U U r U U U w U U U U U
d O U O O O O O O O O O a.O O O U O O O O O

~'a a a, y -'' ~ a~a _ _ s ', Q,p.a.'' T x T T T T T T T T 7, T T T T
o T 0 0 ~ 0 0 0 0 O N ~ C C C C C C C C C C C C O ~ p ~
s ~ ~ s ,C s LZi C ~ a~v v a~a~a a~ a a ~ a~a a~ Vii,U OL7l~
~ ~ a ~ s s s s s s s s s s s .~ ~ ~ ~ ~ GL
r~.E'CGN Q,0Ø A..LLOrG. 0.CLN fS.OrGL N M '~~t >, C

s O

C
>,T >, >, .R C
T i.T T T T T T T T 7,N T ~ s s T T T T .c T Q,n, O.
i~ 0 0 0 '-T
E C C C C a c o c a ~ o x ~ O ~ p .'Cs .'c _ ~ '-I s .'es r s s .cs .cs s U .'c~'z'V ~ s P,G.Is,N
d' G.A.C4 fs,0.0, pr1SØ,C, Gs.Y t~.N M ~ G, x a, x .~~ ~ ~n'~M'UI v, ."1".M
s U U O O O O O O O O O O x U x O O
O, N .r~.r O O O
Z O O O O O O

I~ 00OvO -~N M d'~ ~OI~ 00O~O .-~N M ~ V WOt~ 00 ~.-i.-w~ N N N N N N N N N N M M M M M M M M M
M M M M M M M M M M M M M M M M M M M M M M

d E

U

o ' a. o ~o r, N O O O O O O O ~nO O O v~v~~n O O O O v~O O O

7- O O O O O O m O O O w o cnO O O O v~viO O O

U U U U

U ~ U ~ U x z z z z U U

U

N N N z z v v z ~ U

U U M

w ~, ~ x x w M M

O ~ M O U O ~ O M O U U U U O
~ U

U

M M M M M M M M M M M M M M
x x x x x x x x x x x x x x x x x M w M M

~ O O U O O U O O

~ O O O O O O O O O O O O U U

>, >, C

s s a n.~
c a > a , , >, >,T

t~t~ O ~ p ~ O _ j T T T T ;~,fl T T T T T T T E y ~ ~ T T T
'fl , s .Cs C E E T C C C C C C C T ~ ~C~ ~ S
C '.
a a N ~ ~ ' ~..Gr~ N ~ ~ ~ 4l ~ A x E~o a~a~ ~

t ~ ~ ~ = M ~ N s t .cs r s s N M etN ~-.r~-..$-.
O C P C CZ

C; G ... .. G V G.?, " . . r ., r . ~. ' T
C C

N N
S

C. G.

T . T 7, C
s T T ~ ~ E

E
a >

x a a s x s , , o ..

_ ~ O O ~ T T T '~~ E T T T 7.T T T 7,T p O

~ T ~ 7 C C C T ~ C C C C C C C C C V V
C

w w z ~ ~ ~ x ~. A ~ ~ ~ ~ ~ ~ ~ ~ ~ T T
c ~ s e s t , , , s .e s , , , s s .e r . . C4. C.U U
CLC4C G FtQ. CL

C~ M fl,~ ~f ~ PnOr CL,N M ~ ., r , , U N x ~.,"'(j III N ~ U
x x U ~ , >. U U

..,x O
U

(~ ~ x x U ~ ~ ~ ~ ~ U V p ~

0 0 0 o z o 0 0 o z z o 0 0 0 0 0 o z o 0 0 OvO .-rN M ~ ~Oh o0 O~O ~ N cnd'v'iv0t~00O~ O

M ~'Wt~' ~ ~ ~ ~''~t~ ~ V'71/71!1V1h Y) V1h VlV1 M

z ..~ ~ ~ ..

V M ~' ~ ~
E

.r o v o ~ v , .n .-i rr .-r v N N

~ ~ O O O O O O O O O O O O

N O O O O O

O O O O O O O O O O O O

O O O O O O O

~ x x x x U U U U U U U

U U U U x S x U x ~ z z ~C

x U U U ~ U U

"

V x x O

~ z o 0 o z o 0 0 0 0 0 0 0 Z x ~ a a~a~~ a~ a a~a~a~a~ a a~

w v w a N ....V V ~

x z o 0 0 0 0 0 0 0 o z o 0 0 0 0 0 N

x U

N

x s s ~ w A4~ ~ ~ ~ ~ ~ ~ x ?, T

C C C

N

C C C Ow CLC1r ~ s t s n C C p a"Q O O O C C C C C C G C G C
"

~ C ; u , ~ ~ ~ ~ s ~ s s te~ s s ~
G

~ s s s ~; , ~, , e .

3 M ~ M M M G,Or P. C, Q.CL.O.Or G4a' p~f1,p,! M
.

T

~ U y y s N N ~ N
N N O O

N

~ ~ x x m x x x x x x x x x x x x ~
z 0 0 0 0 0 0 0 0 0 0 0 0 o z z U U , ~

~f ~n~O t~ 00OvO .-iN M V v7v0t~00 O~O

~ N M ~O ~O~O ~D ~O~Ot~t~ t~l~r r I~I~t~ t~00 ~O ~O~D

M M M M M M M M M M M M M M M

Q M M M M M

z ..

..
o, n, a o °i ~v E r can E ° E ,N o ,r ~ .-, o .-, .~ o .-, o C3. N O V O~ C~ V n V O O~
N ~ .yp .-w .D M -~p ~ ~O
N O O O O O O O O
O O O O O O O O
U U U U U
x x x x x U U x V x V V
N N U N U N N
U U U U U
O O O O O
, , , , a ~ o o ~ ~ x o ~ o o O o 0 0 x U' ~U
N
N ~ ~ N ~
a, i, t s C ~ G
y ar O, N ,= a a, >, ~ a~ e~ pt,~ Q~
~ t ,~ L ~, ~ ~ ~,y u. ~y pG a, a. o E E n. E n.
a a >, s _ ~ H
A4 Z~~ O O O O O O O H
.-r N M ~ V1 vC t~ o0 r~
p ~ M M M M M M M
z U

O M

t~

N O O O O O O O O O O O O O O O

O O O O O O O O O O O O O O O

U U

x x ~ x x x x x x x x x x U

N V U U

O x x O V U

N N

x x U U

a~a~ a w a~ a a~a~ a~d a 04 x x N
Cx O O O O O O O O O O O O O O O

U

a N

C

c x L
' U
s _E
t L s .CL ~,Q N N T L L L
a T x a T
~ o U o O M ~
04 W ~ fi7~
a x U
V

N '~,1 ~ x Q U O v~V a c ~ U V U U N jN~
U Z ~ C~~ U U U U U
U

x x x x x x x x x x x x x x x ~ 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 O ~ N M V' V1~Dt~
.-i.i..-~~ ~ ..i ..

Example 35 Receptor binding data were measured by the binding assay de-scribed above for the compounds listed below.
The results are shown in Table 2 [sic].
Table 2 [sic]
Receptor binding data (Ki values) Compound ETA [nM] ETH [nM]

I.89 86 9300 I-103 0.4 29 I-96 0.6 56

Claims (44)

1. A compound having the formula:

wherein:

R1 is OH and OR7;
R7 is a) an alkali metal cation, one equivalent of an alkaline earth metal cation, an ammonium cation or an organic ammonium ion;

b) C3-8-cycloalkyl optionally substituted by one to three C1-4-alkyl;

c) C1-8-alkyl optionally substituted by one to five halogen or one of C1-4-alkoxy, C1-4-alkylthio, and phenyl or phenoxy optionally substituted by one to five halogen, or one to three of nitro, cyano, C1-4-alkyl, C1-4haloalkyl, C1-4-alkoxy, C1-4-haloalkoxy and C1-4-alkylthio;

d) C3-6-alkenyl or C3-6-alkynyl optionally substituted with one to five halogen; and e) phenyl optionally substituted with one to five halogen, or one to three of nitro, cyano, C1-4-alkyl, C1-4-haloalkyl, C1-4-alkoxy, C1-4-haloalkoxy and alkylthio;

R2 and R3 are, independently, halogen, C1-4-alkyl, C1-4-haloalkyl, C1-4-alkoxy, C1-4-haloalkoxy and C1-4-alkylthio;

X is N or CR8;

R8 is H or, together with R3, forms a 5- or 6-membered alkylene or alkenylene ring, one of the methylene group of the ring being optionally replaced by oxygen;

R4 and R5 are identical or different and have the following meaning: phenyl or naphthyl which are optionally substituted by one or more of halogen, nitro, cyano, hydroxyl, mercapto, amino, C1-4-alkyl, C1-4-haloalkyl, C1-4-alkoxy, C1-haloalkoxy, C1-4-alkylthio, C1-4-alkylamino, di-C1-4-alkylamino, C1-4-akylcarbonyl or C1-4-alkoxycarbonyl; or phenyl or naphthyl which are connected together in the ortho positions via a direct linkage, a methylene, ethylene or ethenylene group, an oxygen or sulfur atom or an SO2-, NH- or N-alkyl group, or C3-C7-cycloalkyl;

R6 is C1-8-alkyl, C3-6-alkenyl, C3-6-alkynyl, or C3-8-cycloalkyl optionally substituted by one or more of halogen, C1-4- alkoxy, C3-6-alkenyloxy, C3-6-alkynyloxy, C1-alkylthio, C1-4-haloalkyl, C1-4-alkylamino, di-C1-4-alkylamino, C1-4-alkylcarbonyl or C1-4-alkoxycarbonyl, or phenyl or phenyloxy optionally substituted by one or more of halogen, nitro, cyano, C1-4-alkyl, C1-4-haloalkyl, C1-4-alkoxy, C1-4-haloalkoxy, C1-4-alkylthio.

Y is sulfur, oxygen or a single bond; and Z is sulfur or oxygen;

with the proviso that R6 is not unsubstituted C1-4-alkyl when R4 is unsubstituted phenyl, Z is oxygen and simultaneously R5 is methyl or hydrogen.
2. The compound of claim 1, wherein R7 is sodium, potassium, an organic ammonium ion, C3-6-cycloalkyl, C1-5-alkyl, C3-6-alkenyl, C3-6-alkynyl, and phenyl optionally substituted by one or more of halogen, nitro, C1-4-alkyl, C1-4-haloalkyl, C1-4-alkoxy, C1-4-haloalkoxy or C1-4-alkylthio.
3. The compound of claim 2, wherein X is CR8.
4. The composition of claim 3, wherein R2 and R3 are, independently, C1-4-alkyl, C1-4-alkoxy, and R8 is H.
5. The compound of claim 4, wherein both Y and Z are oxygen.
6. The compound of claim 5, wherein R6 is C1-5-alkyl, C3-6-alkenyl, C3-6-alkynyl, or C3-6-cycloalkyl.
7. The compound of claim 6, wherein both R4 and R5 are phenyl.
8. The compound of claim 7, wherein R6 is methyl.
9. The compound of claim 8, wherein R7 is sodium, potassium, C3-6-cycloalkyl, C1-5-alkyl.
10. A compound having the formula:

wherein:

X is CH;
Y is oxygen;
Z is oxygen;
R is CO2H;
R2 is methyl;
R3 is methyl;
R4 is phenyl;
R5 is phenyl, and R6 is methyl, and salts thereof.
11. The compound of claim 10, wherein the compound is in the form of an optically active enantiomer.
12. The compound of claim 11, wherein the enantiomer is the S enantiomer, and salts thereof
13. The compound of claim 11, wherein the enantiomer is the pure form of the S enantiomer.
14. The compound of claim 11, wherein the enantiomer is the R enantiomer, and salts thereof
15. The compound of claim 11, wherein the enantiomer is the pure form of the R enantiomer.
16. A pharmaceutical formulation comprising a compound having the formula:

wherein:

X is CH;
Y is oxygen;
Z is oxygen;
R is CO2H;
R2 is methyl;
R3 is methyl;
R4 is phenyl;
R5 is phenyl;
R6 is methyl; and pharmaceutically acceptable salts thereof, dispersed in a pharmaceutical buffer, diluent or excipient.
17. The formulation of claim 16, formulated for delivery via oral, parenteral, subcutaneous, intravenous, intramuscular, intraperitoneal, sublingual, transdermal or nasopharyngeal routes.
18. The formulation of claim 16, wherein the compound is in a solid form.
19. The formulation of claim 16, wherein the compound is in a liquid form.
20. The formulation of claim 16, wherein the compound is formulated as an uncoated tablet, as a coated tablet, a capsule, a powder, a granule, a suppository, a solution, an ointment, a cream, a vapour or a spray.
21. The formulation of claim 16, further comprising one or more of a tablet binder, a filler, a preservative, a tablet disintegrant, a flow regulator, a plasticizer, a wetting agent, a dispersant, an emulsifier, a solvent, a release-slowing agent, an antioxidant, or a propellant gas.
22. The formulation of claim 16, wherein the compound is in the form of an optically active enantiomer.
23. The formulation of claim 22, wherein the enantiomer is the S enantiomer, and salts thereof.
24. The formulation of claim 22, wherein the enantiomer is the pure form of the S enantiomer.
25. The formulation of claim 22, wherein the enantiomer is the R enantiomer, and salts thereof.
26. The formulation of claim 22, wherein the enantiomer is the pure form of the R enantiomer.
27. A compound of the formula:

wherein:

X is CH;
Y is oxygen;
Z is oxygen;
R is CO2H;
R2 is methoxy;
R3 is methoxy;
R4 is phenyl;
R5 is phenyl, and R6 is methyl, and salts thereof.
28. The compound of claim 27, which is in the form of an optically active enantiomer.
29. The compound of claim 28, wherein the enantiomer is the S enantiomer, and salts thereof.
30. The compound of claim 28, wherein the enantiomer is the pure form of the S enantiomer.
31. The compound of claim 28, wherein the enantiomer is the R enantiomer, and salts thereof.
32. The compound of claim 28, wherein the enantiomer is the pure form of the R enantiomer.
33. A pharmaceutical formulation comprising a compound having the formula:

wherein:

X is CH;
Y is oxygen;
Z is oxygen;
R is CO2H;
R2 is methoxy;
R3 is methoxy;

R4 is phenyl;
R5 is phenyl, and R6 is methyl, and pharmaceutically acceptable salts thereof, dispersed in a pharmaceutical buffer, diluent or excipient.
34. The formulation of claim 33, formulated for delivery via oral, parenteral, subcutaneous, intravenous, intramuscular, intraperitoneal, sublingual, transdermal or nasopharyngeal routes.
35. The formulation of claim 33, wherein the compound is in a solid form.
36. The formulation of claim 33, wherein the compound is in a liquid form.
37. The formulation of claim 33, wherein the compound is formulated as an uncoated tablet, as a coated tablet, a capsule, a powder, a granule, a suppository, a solution, an ointment, a cream, a vapor or a spray.
38. The formulation of claim 33, further comprising one or more of a tablet binder, a filler, a preservative, a tablet disintegrant, a low regulator, a plasticizer, a wetting agent, a dispersant, an emulsifier, a solvent, a release-slowing agent, an antioxidant, or a propellant gas.
39. The formulation of claim 33, wherein the compound is in the form of an optically active enantiomer.
40. The formulation of claim 39, wherein the enantiomer is the S enantiomer, and salts thereof.
41. The formulation of claim 39, wherein the enantiomer is the pure form of the S enantiomer.
42. The formulation of claim 39, wherein the enantiomer is the R enantiomer, and salts thereof.
43. The formulation of claim 39, wherein the enantiomer is the pure form of the R enantiomer.
44. A pharmaceutical formulation comprising a compound as claimed in any one of claims 1 to 9, dispersed in a pharmaceutical buffer diluent or excipient.
CA002201785A 1994-10-14 1995-10-07 New carboxylic acid derivatives, their preparation and their use Expired - Lifetime CA2201785C (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
DE4436851 1994-10-14
DEP4436851.8 1994-10-14
DE19533023.4 1995-09-07
DE19533023A DE19533023B4 (en) 1994-10-14 1995-09-07 New carboxylic acid derivatives, their preparation and use
PCT/EP1995/003963 WO1996011914A1 (en) 1994-10-14 1995-10-07 New carboxylic acid derivatives, their preparation and their use

Publications (2)

Publication Number Publication Date
CA2201785A1 CA2201785A1 (en) 1996-04-25
CA2201785C true CA2201785C (en) 2006-08-29

Family

ID=6530833

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002201785A Expired - Lifetime CA2201785C (en) 1994-10-14 1995-10-07 New carboxylic acid derivatives, their preparation and their use

Country Status (32)

Country Link
US (15) USRE42462E1 (en)
EP (2) EP1110952B9 (en)
JP (6) JP3957748B2 (en)
KR (1) KR100438339B1 (en)
CN (3) CN1142918C (en)
AT (2) ATE204568T1 (en)
BR (1) BR9509338A (en)
CA (1) CA2201785C (en)
CZ (1) CZ294603B6 (en)
DE (4) DE19533023B4 (en)
DK (1) DK0785926T3 (en)
ES (2) ES2226996T3 (en)
FI (1) FI120492B (en)
FR (1) FR08C0041I2 (en)
GR (1) GR3036931T3 (en)
HK (2) HK1066541A1 (en)
HR (2) HRP950517B1 (en)
HU (1) HU220621B1 (en)
IL (1) IL115560A (en)
LU (1) LU91487I2 (en)
MX (1) MX9702658A (en)
NL (1) NL300361I2 (en)
NO (2) NO308846B1 (en)
NZ (1) NZ294849A (en)
PL (1) PL186850B1 (en)
PT (1) PT785926E (en)
RU (1) RU2180335C2 (en)
SI (1) SI9520110A (en)
TW (1) TW577880B (en)
UA (1) UA45985C2 (en)
WO (1) WO1996011914A1 (en)
ZA (1) ZA958642B (en)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19533023B4 (en) * 1994-10-14 2007-05-16 Basf Ag New carboxylic acid derivatives, their preparation and use
DE19536891A1 (en) * 1995-10-04 1997-04-10 Basf Ag New amino acid derivatives, their production and use
DE19614534A1 (en) * 1996-04-12 1997-10-16 Basf Ag New carboxylic acid derivatives, their production and use
DE19614533A1 (en) * 1996-04-12 1997-10-16 Basf Ag New alpha-hydroxy acid derivatives, their production and use
DE19636046A1 (en) * 1996-09-05 1998-03-12 Basf Ag New carboxylic acid derivatives, their production and use as mixed ET¶A¶ / ET¶B¶ receptor antagonists
US6448248B1 (en) 1996-12-18 2002-09-10 Abbott Laboratories Heterocyclic carboxylic acid derivatives, the production and use thereof as endothelin receptor antagonists
US6030975A (en) * 1997-03-14 2000-02-29 Basf Aktiengesellschaft Carboxylic acid derivatives, their preparation and use in treating cancer
JP2001514254A (en) * 1997-09-04 2001-09-11 ビーエーエスエフ アクチェンゲゼルシャフト Novel carboxylic acid derivatives, their preparation and their use as mixed ETA / ETB endothelin receptor antagonists
CZ299741B6 (en) * 1997-09-26 2008-11-05 Abbott Gmbh & Co. Kg Endothelin antagonist and renin-angiotensin system (RAS) inhibitor as a combined composition, use thereof, pharmaceutical composition in which the combination is comprised and process for preparing such composition
DE19743142A1 (en) * 1997-09-30 1999-04-01 Knoll Ag Combination pharmaceutical preparations
DE19743143A1 (en) * 1997-09-30 1999-04-01 Knoll Ag Combination pharmaceutical preparations
DE19743681A1 (en) * 1997-10-02 1999-04-08 Knoll Ag Use of endothelin receptor antagonists to prevent transplant rejection
EP1027338A2 (en) * 1997-10-31 2000-08-16 Basf Aktiengesellschaft New carboxylic acid derivatives, carrying amido side-chains; production and use as endothelin receptor antagonists
DE19750529A1 (en) 1997-11-14 1999-05-20 Basf Ag New heterocyclic alpha-hydroxycarboxylic acid derivatives useful for treating hypertension, chronic coronary insufficiency, asthma, prostate cancer etc.
DE19806438A1 (en) * 1998-02-17 1999-08-19 Basf Ag New pyrimidinyloxy-propionic acid derivatives useful as endothelin receptor antagonists in treatment of e.g. cardiac insufficiency, restenosis, hypertension, kidney failure, asthma and prostate cancer
DE19809635A1 (en) * 1998-03-06 1999-09-09 Basf Ag Method for the preparation of sulfanyl-type endothelin receptor antagonists
DE19850301A1 (en) * 1998-10-30 2000-05-04 Basf Ag Process for the resolution of racemates of 2-hydroxypropionic acids
US7566452B1 (en) 1999-05-04 2009-07-28 New York University Cancer treatment with endothelin receptor antagonists
DE10002393A1 (en) * 2000-01-20 2001-07-26 Basf Ag Preparation of 3,3-diphenyl-2,3-epoxy-propionate esters from 3-phenyl-cinnamic acid esters, using method which is suitable for industrial scaling and gives high enantiomeric purity
US8168616B1 (en) 2000-11-17 2012-05-01 Novartis Ag Combination comprising a renin inhibitor and an angiotensin receptor inhibitor for hypertension
DE10064797A1 (en) * 2000-12-22 2002-06-27 Knoll Ag Combination pack useful for the treatment of e.g. deep vein thrombosis and post-operative thrombosis, containing oral and parenteral formulations of thrombin inhibitor prodrugs
WO2002064573A1 (en) * 2001-02-14 2002-08-22 Abbott Gmbh & Co. Kg Novel carboxylic acid derivatives containing alkyl substituted triazines, production of the same and use thereof as endothelin receptor antagonists
ES2262567T3 (en) 2001-03-20 2006-12-01 Schwarz Pharma Ag NEW USE OF A PEPTIDIC COMPOSITE CLASS FOR THE TREATMENT OF NON-NEUROPATIC INFLAMMATORY PAIN.
DK1243263T3 (en) 2001-03-21 2003-03-17 Sanol Arznei Schwarz Gmbh Hitherto unknown use of a class of peptide compounds to treat allodynia or other various types of chronic or phantom pain
US6772708B2 (en) * 2001-10-30 2004-08-10 The Procter And Gamble Company Wetness indicator having improved colorant retention
DE10259382A1 (en) * 2002-12-18 2004-07-01 Abbott Gmbh & Co. Kg 3-Substituted 3,4-dihydro-thieno [2,3-d] pyrimidin-4-one derivatives, their preparation and use
US20040204422A1 (en) 2003-04-14 2004-10-14 Abbott Gmbh & Co. Kg. N-[(Piperazinyl)hetaryl]arylsulfonamide compounds
GB0327839D0 (en) 2003-12-01 2003-12-31 Novartis Ag Organic compounds
TW200605867A (en) 2004-03-17 2006-02-16 Novartis Ag Use of organic compounds
EA013591B1 (en) 2004-04-16 2010-06-30 Шварц Фарма Аг Use of peptidic compounds for the prophylaxis, relief and treatment of headache and painful conditions associated with or cortical spreading depression (csd) associated disorders
EP1604656A1 (en) 2004-06-09 2005-12-14 Schwarz Pharma Ag Novel use of peptide compounds for treating amyotrophic lateral sclerosis (ALS)
EP1781276B1 (en) 2004-08-27 2010-06-23 UCB Pharma GmbH Use of peptide compounds for treating bone cancer pain, chemotherapy- and nucleoside-induced pain
DE102005025161A1 (en) * 2005-06-01 2006-12-07 Phenion Gmbh & Co. Kg New pyrimidine- and triazine derivatives are peroxisome proliferator activated receptor modulators, useful to treat e.g. diabetes, insulin resistance, obesity, hyperlipidemia, cardiovascular diseases and Alzheimer's disease
KR20080095885A (en) * 2006-01-20 2008-10-29 쉐링 코포레이션 Benzenesulfonyl-chromane, thiochromane, tetrahydronaphthalene and related gamma secretase inhibitors
BRPI0709950A2 (en) * 2006-04-13 2011-08-02 Actelion Pharmaceuticals Ltd use of bosentan in the preparation of a drug for the treatment of early idiopathic pulmonary fibrosis and use of endothelin receptor antagonist
AR061476A1 (en) 2006-06-15 2008-08-27 Sanol Arznei Schwarz Gmbh PHARMACEUTICAL COMPOSITION WITH SYNERGIC ANTI-CONVULSIVE EFFECT
PT2101777E (en) 2006-12-12 2015-09-18 Gilead Sciences Inc Composition for treating a pulmonary hypertension
EP2118073A2 (en) 2007-02-02 2009-11-18 Concert Pharmaceuticals Inc. Selective endothelin type-a antagonists
MX2010001255A (en) * 2007-07-31 2010-12-06 Gilead Colorado Inc Metabolites and derivatives of ambrisentan.
US20090069353A1 (en) * 2007-09-12 2009-03-12 Protia, Llc Deuterium-enriched ambrisentan
DE102008037324A1 (en) 2008-08-11 2010-02-18 Ratiopharm Gmbh Pharmaceutical formulation for pulmonary reduction of blood pressure
US8404840B2 (en) * 2008-11-05 2013-03-26 Msn Laboratories Limited Process for the preparation of endothelin receptor antagonists
DE202009009917U1 (en) 2009-07-21 2010-02-11 Ratiopharm Gmbh Ambrisentan in specific crystalline form
WO2010091877A2 (en) 2009-02-13 2010-08-19 Ratiopharm Gmbh Process for producing ambrisentan
EP2712865B1 (en) 2009-07-10 2016-03-16 Cadila Healthcare Limited Improved process for the preparation of ambrisentan
US20110046163A1 (en) * 2009-08-20 2011-02-24 Moore Ii Bob M Furanopyrimidine cannabinoid compounds and related methods of use
CA2782110A1 (en) * 2009-12-07 2011-06-16 Johns Hopkins University N-acyloxysulfonamide and n-hydroxy-n-acylsulfonamide derivatives
WO2011071947A2 (en) 2009-12-07 2011-06-16 Johns Hopkins University Bis-acylated hydroxylamine derivatives
CA2792473A1 (en) 2010-03-15 2011-09-22 Natco Pharma Limited A process for the preparation of highly pure ambrisentan
US20130184490A1 (en) * 2010-08-04 2013-07-18 Natco Pharma Limited Process to prepare s-2-hydroxy-3-methoxy-3,3-diphenyl propionic acid
AU2011315891B2 (en) 2010-10-15 2015-08-13 Gilead Sciences, Inc. Compositions and methods of treating pulmonary hypertension
EP2476670A1 (en) 2011-01-07 2012-07-18 Zentiva, K.S. Stable solid salts of ambrisentan
CN102276536B (en) 2011-06-10 2015-04-29 中国科学院化学研究所 Preparation method of optically pure (+)-ambrisentan and optically pure (+)-darusentan
CN103012280B (en) * 2011-09-22 2015-04-29 江苏康缘药业股份有限公司 Method for preparing ambrisentan
KR101855506B1 (en) 2011-10-13 2018-05-08 주식회사 동진쎄미켐 Polymer having aromatic ring and under-layer composition of resist including the same
IN2014MN00850A (en) 2011-10-19 2015-04-17 Cipla Ltd
PL2867214T3 (en) 2012-06-29 2017-02-28 Kern Pharma, S.L. Preparation process of carboxylic acid derivatives and intermediates thereof
CN103524425A (en) * 2012-07-04 2014-01-22 天津药物研究院 Crystal form V of ambrisentan as well as preparation method and application thereof
CN103524424A (en) * 2012-07-04 2014-01-22 天津药物研究院 Crystal form VI of ambrisentan as well as preparation method and application thereof
CN104098462B (en) * 2013-04-12 2017-11-17 江苏豪森药业集团有限公司 The method for splitting of the diphenyl-propionic acid racemoid of 2 hydroxyl, 3 methoxyl group 3,3
CN104592129B (en) * 2013-10-30 2019-04-16 武汉启瑞药业有限公司 A kind of improved method for preparing ambrisentan
CN103709106A (en) * 2013-12-06 2014-04-09 石家庄博策生物科技有限公司 Stereoselectivity preparation method for Letairis
CN104744231A (en) * 2013-12-26 2015-07-01 天津药物研究院 Method for splitting 2-hydracrylicacid racemate
CN105801404B (en) * 2014-12-31 2019-01-08 辽宁远大诺康生物制药有限公司 A kind of S-2- hydroxy-3-methoxy -3,3- diphenyl-propionic acid and preparation method thereof
CN106699626B (en) * 2015-11-13 2019-08-16 辽宁远大诺康生物制药有限公司 A kind of preparation method of 2- hydroxy-3-methoxy -3,3- diphenylprop hydrochlorate raceme
EP3235496A1 (en) 2016-04-19 2017-10-25 Noorik Biopharmaceuticals AG Treatment of acute renal failure
CN109705042B (en) * 2017-10-26 2021-12-21 正大天晴药业集团股份有限公司 Preparation method of ambrisentan
WO2024092240A1 (en) 2022-10-28 2024-05-02 Chinook Therapeutics, Inc. Treatment of iga nephropathy using an endothelin receptor antagonist and an april binding antibody

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE403578C (en) 1924-10-02 Walter Beige Process for internal enameling of pipes
JPS5729445B2 (en) 1974-06-25 1982-06-23
GB8912700D0 (en) 1989-06-02 1989-07-19 Shell Int Research Herbicidal compounds
DE68914197T2 (en) 1988-06-20 1994-11-10 Ihara Chemical Ind Co Alkanoic acid derivatives and herbicidal agents.
JP2771604B2 (en) * 1988-06-20 1998-07-02 クミアイ化学工業株式会社 Novel alkanoic acid derivatives as herbicides and their active ingredients
JPH0331266A (en) 1989-06-27 1991-02-12 Nissan Chem Ind Ltd Pyrimidine derivative and herbicide
US5270289A (en) 1989-07-19 1993-12-14 Schering Aktiengesellschaft Herbicidal dimethoxy pyrimidinyloxy-fluorinated acids and salts
IL94999A (en) 1989-07-19 1994-10-07 Schering Ag alpha-pyrimidinyloxy (thio)- and alpha-triazinylo xy (thio) carboxylic acid derivatives and herbici dal compositions containing the same
FR2650365B1 (en) 1989-07-28 1991-11-22 Caillau Ets QUICK COUPLING
JPH03240777A (en) 1990-02-20 1991-10-28 Ube Ind Ltd Fatty acid derivative, production thereof and herbicide
DE4029648A1 (en) 1990-09-19 1992-03-26 Hoechst Ag 4-ANILINO-PYRIMIDINE, METHOD FOR THE PRODUCTION THEREOF, AGENTS CONTAINING IT AND THEIR USE AS FUNGICIDES
CA2053603A1 (en) 1990-10-19 1992-04-20 Katsumasa Harada 3-alkoxyalkanoic acid derivative, process for preparing the same and herbicide using the same
JPH05125058A (en) * 1990-10-19 1993-05-21 Ube Ind Ltd 3-alkoxyalkanoic acid compound, its intermediate and production thereof, and herbicide
DE4035758A1 (en) 1990-11-08 1992-05-14 Schering Ag New alpha-pyrimidinyl:oxy(thio) and alpha-triazinyl:oxy(thio) carboxylic acids - used as herbicides, fungicides and as plant growth regulators
JP2730021B2 (en) 1991-05-31 1998-03-25 宇部興産株式会社 3-Benzyloxyalkanoic acid derivative, its production method and herbicide
JP2730022B2 (en) * 1991-06-07 1998-03-25 宇部興産株式会社 3-Alkoxybutylyl imidazole derivatives, their production and herbicides
EP0517215B1 (en) 1991-06-07 1998-09-02 Ube Industries, Ltd. Pyrimidine or triazine derivative, process for preparing the same and herbicide using the same
DE4123469A1 (en) 1991-07-16 1993-01-21 Basf Ag Herbicidal compsns. contg. safener - comprising N-di:chloro-acetyl-di:aza-cycloalkane deriv.
WO1993012094A1 (en) * 1991-12-10 1993-06-24 Hoechst Schering Agrevo Gmbh Pyrimidinyl- or triazinyl-oxy(or thio)aldehyde derivatives and their use as herbicides or plant-growth regulators
DE4142570A1 (en) 1991-12-21 1993-06-24 Basf Ag GLYCOLALDEHYDE AND MILK ACID DERIVATIVES, THEIR PREPARATION AND USE
DE4201875A1 (en) 1992-01-24 1993-07-29 Basf Ag THIOCARBONSAEUREDERIVATE, PROCESSES AND INTERMEDIATE PRODUCTS FOR THEIR MANUFACTURE
US5376620A (en) 1992-04-17 1994-12-27 Ube Industries, Ltd. Sulfonamide derivative, process for preparing the same and herbicide using the same
CA2110500A1 (en) * 1992-06-17 1993-12-23 Christoph Luthy Pyrimidinyl- and tetrazinyl compounds with herbicidal activity
US5541148A (en) 1992-07-08 1996-07-30 Ciba-Geigy Corporation Selective safened herbicidal composition comprising 2-ethoxycarbonyl-3-(4,6-dimethoxypyrimidine-2-yl) oxy-pyridine and an acylsulfamoylphenyl-urea safener
EP0671880A1 (en) 1992-07-08 1995-09-20 Ciba-Geigy Ag Selective herbicidal composition
JP2985992B2 (en) 1992-07-21 1999-12-06 宇部興産株式会社 3-Alkoxy-N-cycloalkylsulfonylalkanoic acid amide derivative, production method thereof and herbicide
DE4313412A1 (en) 1993-04-23 1994-10-27 Basf Ag 3- (Het) aryl-carboxylic acid derivatives, processes and intermediates for their preparation
DE4313413A1 (en) 1993-04-23 1994-10-27 Basf Ag 3- (Het) aryloxy (thio) carboxylic acid derivatives, processes and intermediates for their preparation
DE69423258T2 (en) * 1993-06-03 2000-07-13 Kanegafuchi Kagaku Kogyo K.K., Osaka Curable composition
DE4335950A1 (en) * 1993-10-21 1995-04-27 Basf Ag Derivatives of 3-hydroxycarboxylic acids, their preparation and use
DE4411225A1 (en) 1994-03-31 1995-10-05 Basf Ag Use of carboxylic acid derivatives as a drug
WO1996000219A1 (en) 1994-06-27 1996-01-04 Ciba-Geigy Ag Pyrimidinyl- and triazinyl-oxy and thio-3-haloalkyl-propionic acid derivatives as herbicides
DE19533023B4 (en) 1994-10-14 2007-05-16 Basf Ag New carboxylic acid derivatives, their preparation and use
MX9702799A (en) 1994-10-21 1997-06-28 Glaxo Wellcome Inc Medicament carrier for dry powder inhalator and process for forming the same.
US6030975A (en) 1997-03-14 2000-02-29 Basf Aktiengesellschaft Carboxylic acid derivatives, their preparation and use in treating cancer
CZ299741B6 (en) 1997-09-26 2008-11-05 Abbott Gmbh & Co. Kg Endothelin antagonist and renin-angiotensin system (RAS) inhibitor as a combined composition, use thereof, pharmaceutical composition in which the combination is comprised and process for preparing such composition
DE19743143A1 (en) 1997-09-30 1999-04-01 Knoll Ag Combination pharmaceutical preparations
DE19754082A1 (en) 1997-12-05 1999-06-10 Knoll Ag Method of combating obesity
DE19850301A1 (en) 1998-10-30 2000-05-04 Basf Ag Process for the resolution of racemates of 2-hydroxypropionic acids
DE10002393A1 (en) 2000-01-20 2001-07-26 Basf Ag Preparation of 3,3-diphenyl-2,3-epoxy-propionate esters from 3-phenyl-cinnamic acid esters, using method which is suitable for industrial scaling and gives high enantiomeric purity
EP1946502B2 (en) 2006-07-12 2017-09-13 Huawei Technologies Co., Ltd. Method for controlling congestion
MX2010001255A (en) 2007-07-31 2010-12-06 Gilead Colorado Inc Metabolites and derivatives of ambrisentan.

Also Published As

Publication number Publication date
US20060160808A1 (en) 2006-07-20
US7601730B2 (en) 2009-10-13
RU2180335C2 (en) 2002-03-10
PL319655A1 (en) 1997-08-18
CN1160396A (en) 1997-09-24
NL300361I1 (en) 2008-12-01
TW577880B (en) 2004-03-01
CZ294603B6 (en) 2005-02-16
NO971675D0 (en) 1997-04-11
FI971529A0 (en) 1997-04-11
CN1142918C (en) 2004-03-24
JP5160797B2 (en) 2013-03-13
US20120088911A1 (en) 2012-04-12
GR3036931T3 (en) 2002-01-31
AU688611B2 (en) 1998-03-12
PL186850B1 (en) 2004-03-31
HRP20040364A2 (en) 2005-06-30
EP1110952B1 (en) 2004-09-29
IL115560A0 (en) 1996-01-19
NO2008015I1 (en) 2008-11-03
NL300361I2 (en) 2009-02-02
WO1996011914A1 (en) 1996-04-25
EP0785926B1 (en) 2001-08-22
US8349843B2 (en) 2013-01-08
US20020052495A1 (en) 2002-05-02
US20040092742A1 (en) 2004-05-13
DE59509541D1 (en) 2001-09-27
LU91487I2 (en) 2008-12-15
EP1110952A1 (en) 2001-06-27
HRP950517A2 (en) 1997-10-31
JP4787184B2 (en) 2011-10-05
FR08C0041I1 (en) 2008-11-28
BR9509338A (en) 1997-11-04
KR970707103A (en) 1997-12-01
FR08C0041I2 (en) 2009-12-18
NZ294849A (en) 1999-04-29
AU3804595A (en) 1996-05-06
JP2007137893A (en) 2007-06-07
ZA958642B (en) 1997-04-14
JP5700378B2 (en) 2015-04-15
US6600043B2 (en) 2003-07-29
DK0785926T3 (en) 2001-10-08
DE59510949D1 (en) 2004-11-04
US20100076188A1 (en) 2010-03-25
NO308846B1 (en) 2000-11-06
CN1293059C (en) 2007-01-03
IL115560A (en) 2003-02-12
JP2007137892A (en) 2007-06-07
CN1923820B (en) 2010-04-21
JP2007126488A (en) 2007-05-24
USRE42477E1 (en) 2011-06-21
USRE42462E1 (en) 2011-06-14
CN1923820A (en) 2007-03-07
US7119097B2 (en) 2006-10-10
CN1513844A (en) 2004-07-21
UA45985C2 (en) 2002-05-15
PT785926E (en) 2002-02-28
NO971675L (en) 1997-06-10
US20060276474A1 (en) 2006-12-07
EP0785926A1 (en) 1997-07-30
FI120492B (en) 2009-11-13
JP2007169295A (en) 2007-07-05
JP3957748B2 (en) 2007-08-15
US6197958B1 (en) 2001-03-06
DE19533023B4 (en) 2007-05-16
DE122008000049I1 (en) 2009-01-29
HRP950517B1 (en) 2004-06-30
US7582647B2 (en) 2009-09-01
HRP20040364B1 (en) 2006-09-30
NO2008015I2 (en) 2012-03-05
JPH10507190A (en) 1998-07-14
US5932730A (en) 1999-08-03
ATE204568T1 (en) 2001-09-15
HUT77443A (en) 1998-04-28
JP4512105B2 (en) 2010-07-28
SI9520110A (en) 1997-12-31
US20070203338A1 (en) 2007-08-30
CA2201785A1 (en) 1996-04-25
ES2162942T3 (en) 2002-01-16
HK1104293A1 (en) 2008-01-11
HU220621B1 (en) 2002-03-28
US20060276645A1 (en) 2006-12-07
ES2226996T3 (en) 2005-04-01
US20130317044A1 (en) 2013-11-28
DE19533023A1 (en) 1996-04-18
US7109205B2 (en) 2006-09-19
EP1110952B9 (en) 2004-12-15
US20110178294A1 (en) 2011-07-21
HK1066541A1 (en) 2005-03-24
MX9702658A (en) 1997-06-28
US5969134A (en) 1999-10-19
JP2012111772A (en) 2012-06-14
ATE277911T1 (en) 2004-10-15
FI971529A (en) 1997-04-11
US7863445B2 (en) 2011-01-04
KR100438339B1 (en) 2004-08-25
CZ113297A3 (en) 1998-03-18
JP4512106B2 (en) 2010-07-28

Similar Documents

Publication Publication Date Title
CA2201785C (en) New carboxylic acid derivatives, their preparation and their use
US6610691B1 (en) Carboxylic acid derivatives, their production and use
PT752854E (en) USE OF CARBOXYLIC ACID DERIVATIVES OF PYRIMIDINE OR TRIAZINE AS DRUGS
CA2283732A1 (en) Novel carboxylic acid derivatives, their preparation and use in treating cancer
US6004988A (en) Carboxylic acid derivatives, their preparation and their use
CZ324199A3 (en) Medicament for inhibiting growth of solid tumor in human and process for preparing thereof
MXPA98008197A (en) Derivatives of novel carboxylic acids, its preparation and its

Legal Events

Date Code Title Description
EEER Examination request
MKEX Expiry

Effective date: 20151007